

Irene Leonor Wapnir, MD, FACS

Department of Surgery, Stanford University School of Medicine
300 Pasteur Drive, H3625A
Stanford, CA 94305-5655
wapnir@stanford.edu

EDUCATIONAL BACKGROUND

1975	Bachelor of Arts, Goucher College, Baltimore, MD
1980	Medical Doctor, Universidad Autonoma Metropolitana, Mexico City
1985	Internship/Residency-General Surgery New York Medical College/Lincoln Hospital
1988	Fellowship in Breast Disease UMDNJ-Robert Wood Johnson Medical School

CERTIFICATION

1986	Diplomat, American Board of Surgery
1996, 2006, 2017	Recertification Board of Surgery
1988, 2000	Instructor, Advanced Trauma Life Support, ACS

MEDICAL LICENSURES

Maryland	1982	Inactive #D28604
New York	1985	Inactive #159400-I
New Jersey	1987	Inactive #50743
California	2000	Present #C50558

ACADEMIC APPOINTMENTS

1985	Clinical Instructor, Surgery. New York Medical College
1987	Assistant Professor of Surgery. New York Medical College
1991-1993	Chief, Division of Comprehensive Breast Services UMDNJ–Robert Wood Johnson Medical School
1988-1995	Assistant Professor of Surgery UMDNJ–Robert Wood Johnson Medical School
1991-1994	Director, Comprehensive Breast Center. Robert Wood Johnson University Hospital
1995-2000	Associate Professor of Surgery UMDNJ–Robert Wood Johnson Medical School
2000-2001	Acting Associate Professor, Stanford University School of Medicine
2001-2012	Associate Professor of Surgery, Stanford University School of Medicine
2005-2019	Chief of Breast Surgery, Division of General Surgery Stanford University School of Medicine
2012-present	Professor of Surgery, Stanford University School of Medicine

OTHER APPOINTMENTS

1985-1986	Attending Surgeon. Surgery and Emergency Medicine New York Medical College Lincoln Hospital
1988-2000	Attending Surgeon. Robert Wood Johnson University Hospital
1993	Member, Clinical Research Center Robert Wood Johnson University Hospital
1994-2000	Member, Cancer Institute of New Jersey
2001-present	Attending Surgeon. Stanford University Medical Center
2001-2004	Co-Director of Surgical Specialties Clinic Stanford University Medical Center
2004-2006	Co-Director, Surgical Oncology Clinic, Stanford Cancer Center
2009-present	Faculty member, Goodman Simulation Center

RESEARCHInvestigator-Initiated and Sponsored Studies

2019- present	A pilot trial of nerve allograft in preserving peripheral nerve sensation following prophylactic mastectomy (co-Investigator)
2019 – present	Comparing types of autologous tissue reconstruction (co-PI)
2018-present	A Randomized Phase II Study Comparing Surgical Excision versus NeOadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma in Situ (NORDIS) (NCT 03909282) (PI)
2017	Tumor Genomic Profiling to Monitor Breast Cancer Progression and Treatment Response (Co-investigator)
2014-2018	Devascularization of the Nipple Areolar Complex Allows a Greater Number of Patients to Successfully Undergo Nipple Areolar Sparing Mastectomy (IRB 32190) (PI)
2013-present	Determining the utility of tattooing axillary lymph nodes undergoing percutaneous biopsy for breast cancer staging (IRB 17233) (PI)
2011-present	Observational study of nipple-areolar complex morphology (IRB 20412) (PI)
2001-present	Molecular Analysis of Cancer Circulating Tumor Cells, and Metastases. (SQL 75026) (IRB 5630) (Collaborator)

Past Investigator-Initiated Studies

1. Radioactive iodide (¹³¹I) Treatment of ¹²⁴I PET/CT detected breast cancers (IRB 14941)
2. Scintigraphic assessment of I⁻ transport in metastatic breast cancer and evaluation of ¹³¹I ablative therapy: Parts I & II (IRB 75362)
3. Immunohistochemical and immunoblot analysis of NIS (Na⁺/I⁻ symporter) in Archival and Frozen Human Tissue Samples (IRB 11005)
4. APLAC: Selective targeting of breast cancer with radioiodide in mice (APLAC 9356)
5. Understanding Etiology and Effective Treatments of Granulomatous Mastitis (IRB 39416)
6. Selective targeting of breast cancer with radioiodide in nude mice (IACUC #6621)
7. SEER database: lumpectomy operations for male breast cancer
8. Evaluation of Recurrence Score in Estrogen Receptor and/or Progesterone Receptor Positive Ipsilateral Breast Tumor Recurrences (IRB 18448)
9. Egg retrieval cryopreservation does not delay breast cancer treatment (IRB 9355)

10. The Role of Nipple Cytology in the Work-Up of Nipple Discharge (IRB 9760)
11. In-vitro detection of breast tissue abnormality (IRB 19674)
12. Breast cancer lymphedema: role of insulin resistance/FOXC2
13. Fate of DCIS after neoadjuvant treatment for HER2 positive invasive breast cancer (IRB 25488)
14. The outcomes of immediate reconstruction of irradiated and non-irradiated breasts using implants and dermamatrix (IRB 14928)
15. Triple Negative Breast Cancers Commonly Present as Palpable Masses (IRB 11486)
16. Rate of Lymph Node Sampling in Patients with Ductal Carcinoma In-Situ (DCIS) (IRB 20845-1)
17. Is lymph node ratio prognostic after neoadjuvant therapy for breast cancer? (IRB 33490)
18. AsBrS Collaborative Nipple Sparing Mastectomy Registry (IRB 25031)
19. A pilot study to assess the utility of indocyanine green (IC-Green) SPY *Elite*™ imaging in the mapping of arm draining lymphatics and nodes during sentinel node biopsy with or without axillary dissection in breast cancer (IRB 21030)
20. The role of SPY *Elite* intra-operative angiography in determining adequate skin perfusion in breast cancer related procedures (IRB 15965)
21. Evaluating NIS expression in breast cancer brain metastases (IRB 16546)
22. Prospective Evaluation of Lymphedema Risk (IRB 16299) (Collaborator)

National Clinical Trials

- | | |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2004-2010 | <p>National Cancer Institute
 NSABP B-37 / IBCSG 27-02 / BIG 1-02:
 <i>A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer.</i>
 Study Chair (National Surgical Adjuvant Breast and Bowel Project)</p> |
| 2002 | <p>National Cancer Institute: Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program
 Phase III Clinical Trial for National Surgical Adjuvant Breast and Bowel Project <i>A Randomized Trial Evaluating the Worth of “Adjuvant” Chemotherapy in Breast Cancer Patients Presenting with Isolated Ipsilateral Breast Tumor Recurrence (IBTR), or Isolated Loco-regional Chest Wall Recurrence (LRR).</i>
 Study Chair (2002 Concept approved, not activated)</p> |

Cooperative Group Trials (Institutional PI)

- | | |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1988-present | <p>NRG Oncology [Legacy National Surgical Adjuvant Breast and Bowel Project (NSABP)]
 Funder: National Cancer Institute
 1988-2000 UMDNJ-Robert Wood Johnson Medical School
 2001-present Stanford University School of Medicine</p> |
| 2014-present | <p>NSABP Foundation
 Role: Institutional PI</p> |

Open to Accrual

- | | |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2014-present | <p>NRG Oncology BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive</p> |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

- 2017-present Breast Cancer (IRB 387)
NRG Oncology BR005 A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery (Suspended)
- 2019-present NRG Oncology BR004 Phase III Paclitaxel/Trastuzumab/Pertuzumab w/Atezolizumab or Placebo in HER2+ Metastatic Breast Cancer

Follow-up /closed

- 2017-present NRG A221405 A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE: Pregnancy Outcome & Safety of Interrupting Tx for women w/endocrine responsive breast cancer)
- 2005-closed NSABP B-37 Randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer (IRB 285) (SQL 95760)
- 2005-closed NSABP B-39 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer (IRB 1220) (SQL 95939)
- 2010-2018 NSABP B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
- 2006-closed NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (IRB 7285)
- 2013-closed NSABP B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy (IRB 15886) (CIRB)
- 2008-closed NSABP B-44 A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH Study) (IRB14598)
- 2010-2018 NSABP B-46I/USOR 07132 A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
- 2011-closed NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (IRB 21104)(CIRB)

2012-closed	<u>NSABP B-49</u> A phase III clinical trial comparing the combination of docetaxel plus cyclophosphamide to anthracycline-based chemotherapy regimens for women with node-positive or high-risk node-negative, HER2-negative breast cancer (CIRB)
2013-closed	<u>NSABP B-50-I/GBG 77 (BO27938)</u> A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (IRB 27212-8)
2014-present	<u>NSABP B-52</u> A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation (CIRB)
2014-2018	<u>NSABP B-54-I</u> Phase III study evaluating Palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patient with hormone-receptor positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy "Penelope B" (IRB 33799)
2004-closed	<u>SOFT</u> Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (IRB 13710) (SQL 95281)
2007-closed	<u>PACCT-1</u> Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial (IRB 8093) (SQL 97680)
2011-closed	<u>DMP-1</u> A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer (IRB 22680)

Current Grants/Funded Studies

2021	Developing an Algorithm and Website for Interview Match Funder: Juliana Lee Foundation Role: PI
2021	OMS I141-A Phase 2, Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (Gene Transfer) Funder: OncoSec Medical Inc. Role: Co-investigator (PI: Telli M) 3% FTE
2020-2021	Pivotal study of the LUM Imaging System for Assisting Intraoperative Detection of Residual Cancer in the Tumor Bed of female Patients with Breast Cancer (CLP0008) Funder: Lumicell, Inc./SBIR-NIH Role: Co-investigator (PI: B. Smith. Harvard / Massachusetts Gen Hosp) 5% FTE
2020-2023	R01EB009055-07 High-Resolution Whole-Breast MRI at 3.0T Funder: NIH/NIBIB Role: Co-investigator (PI: B. Hargreaves) 2% FTE

2019-2024	A Novel Approach to Breast Conservation Surgery: Mixed Reality Tumor Visualization and Localization Funder: Stanford Cancer Center Role: Co-PI (PI: B. Daniel) 5% FTE
2019-2023	W81XWH1910740 Biomarker driven targeted therapy for late-recurring ER-positive breast cancer Funder: USAMRAA Role: Co-Investigator (PI: G. Sledge)
2019-2021	Understanding Fibroblast Activation, Clonal Proliferation and Chromatin Accessibility in Solid Tumor Stroma Funder: Stanford Cancer Institute-Goldman Sachs Foundation Cancer Research Fund (SCI-GSF) Role: Co-investigator (PI: J. Norton) 1% FTE
2019-2021	Commissioning and Clinical Evaluation of a Breast-Dedicated PET Camera with 1 Millimeter Spatial Resolution Funder: Stanford Cancer Institute Role: Co-PI (PI: C. Levin) 0.5% FTE
2018-2021	A Randomized Phase II Study Comparing Surgical Excision Versus NeOadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma in Situ (NORDIS) Funder: William Foundation Role: PI
2018-2020	1R01CA212138-01 Feasibility Study Phase C: Expansion into Multiple Institutions for Training in the use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects with Breast Cancer. Funder: NIH R-01 Role: Co-investigator/Institutional PI (PI: B. Smith. Harvard / Massachusetts General Hospital) 5% FTE
2014-2021	3U10CA180816-02S1 Stanford University NCTN- Network Lead Academic Site Funder: National Institutes of Health Role: Institutional co-PI (PI: H. Wakelee) 1% FTE
2013-2024	5PO1CA04960526 Bone Marrow Grafting for Leukemia and Lymphoma Funder: National Institutes of Health Role: Co-investigator (PI: R Negrin) 1% FTE
<u>Submitted/Not Funded</u>	
2019-2024	Targeted MicroRNA Treatment and Imagine of Triple-Negative Breast Cancer using Rationally Engineered Extracellular Vesicles Funder: NIH Role: Collaborator (PI: R. Paulmurugan) 3% FTE
2018-2022	12188505 The Role of Ideal Affect in Patient-Physician Interaction Funder: NIH Role: Co-investigator (PI: J. Tsai, PhD) 5% FTE

2017-2021	Integrated experimental and in silico modeling of breast cancer metastasis Funder: Department of Defense Era of Hope Role: Co-investigator (PI: C. Curtis) 5% FTE
2017-2019	Real-time imaging of metabolic margin metabolic status for breast-conserving surgery Funder: NIH/USAMRAA Role: Co-investigator (PI: G. Pratz, PhD) 5% FTE
2018-2019	A Pilot Trial of Nerve Allograft in Preserving Nipple Sensation After Mastectomy Funder: The Plastic Surgery Foundation Role: Collaborator (PI: D. Nguyen) 1% FTE

Previous Grants

1989	DNA content and oncogene expression in regionally metastatic breast cancer Funder: General Research Support Grant Role: PI
1992	Stereotactic biopsy of nonpalpable breast lesions Funder: Fifth District AHEPA Cancer Research Foundation, Inc. Role: PI
1992	Detection of an invasive phenotype in breast cancer using in situ hybridization for procollagen type I and III Funder: Foundation of University of Medicine and Dentistry of New Jersey Role: PI
1993	Tumor volume and PECAM-1 in breast cancer Funder: Fifth District AHEPA Cancer Research Foundation Role: PI
1994	Detection of platelet activation in metastatic breast cancer using a P-selection antibody and flow cytometry Funder: Fifth District AHEPA Cancer Research Foundation Role: PI
1997-1998	The breast iodide transporter protein in carcinoma of the breast. Funder: Fifth District AHEPA Cancer Research Foundation Role: PI
2001	Radioiodide ablation of breast cancer xenografts as a therapeutic model for human breast cancer Funder: Iris F Litt Fund of the Institute for Research on Women and Gender, Stanford University School of Medicine Role: PI
1999-2003	Scintigraphic assessment of I⁻ transport in metastatic breast and evaluation of ¹³¹I ablative therapy Funder: Susan G. Komen Breast Cancer Foundation Role: PI
2001-2004	Selective targeting of breast cancer with radioiodide in nude mice. Funder: California Breast Cancer Research Program Role: PI

- 2005-2007 **Susan G. Komen Interdisciplinary Breast Fellowship**
Funder: Susan G. Komen Foundation
Role: PI
- 2007-2008 **Developing and imaging brain Metastases in a rodent model with iodide-transporting/ ER-negative breast cancer cell lines**
Funder: Stanford Cancer Center Developmental Cancer Research Award in Translational Science
Role: PI
- 2007-2009 **Multinuclear MRI of breast tumors**
Funder: CA Breast Cancer Research Program
Role: Co-PI (PI: B Hargreaves)
- 2007-2009 **Susan G. Komen Interdisciplinary Breast Fellowship**
Funder: Susan G. Komen Foundation
Role: PI
- 2008-2010 **A pilot study to determine radioiodide accumulation and dosimetry in breast cancers using ¹²⁴I-PET/CT imaging**
Funder: Stanford Center for Clinical and Translational Education and Research
Role: PI
- 2010-2011 **Evaluation of Recurrence Score in estrogen receptor and/or progesterone receptor positive ipsilateral breast tumor recurrences**
Funder: Genomic Health Inc.
Role: PI
- 2006-2011 CA34233-NIH **Stanford Cancer Center Lymphoma Program Project**
Clinical and Laboratory Studies of Malignant Lymphoma
Role: Co-Investigator (PI: Ron Levy)
- 2008-2012 **CD154 Gene Transfer Vaccine for Mantle Cell Lymphoma Post-Transplant**
Funder: Alliance for Cancer Gene Therapy
Role: Co-Investigator (PI: R Levy)
- 2009-2013 **From Bench to Bedside: Treatment of Breast Cancer Brain Metastasis with ¹³¹I and Radiosensitizers**
Funder: Susan G. Komen for the Cure
Role: PI
- 2010-2013 BCRP W81XWH-11-1-0070 **Intra-operative Cerenkov imaging for guiding breast cancer surgery and assessing tumor margins**
Funder: Department of Defense
Role: Postdoctoral Mentor to G. Praxt
- 2010-2013 6283-11 **Immunotransplant for Mantle Cell Lymphoma: A Phase I/II Study**
Funder: The Leukemia & Lymphoma Society
Role: Co-Investigator (PI: R Levy)
- 2011-2014 **The role of SPY Elite intra-operative angiography in determining adequate skin perfusion in breast cancer related procedures**
Funder: Life Cell
Role: Co-investigator (PI: G Gurtner)
- 2013-2014 **Stem cells in breast cancer brain metastasis**

- 2014-2015 Funder: Geneva Foundation
Role: effort as needed (PI: G Sledge)
Impact of the Oncotype DX DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma In Situ
Funder: Genomic Health Inc.
Role: PI
- 2013-2016 **Detection of circulating free DNA in patients with solid tumors**
Funder: Guardant Health
Role: PI
- 2016 22MB-0001 **Pilot Forum for Mental Health Providers: Bridging Gaps in Breast Cancer Care**
Funder: State of California Breast Cancer Research Program
Role: PI
- 2016 AVB-620-C-001 **A phase 1 trial of AVB-620 in women with primary, non-recurrent breast cancer undergoing surgery**
Funder: Avelas Bioscience
Role: Institutional PI
- 2016-2018 **Analysis of skin perfusion changes in two staged nipple-sparing mastectomies using the Spy™ Elite imaging system.**
Funder: Novadaq Technologies, Inc./Stryker
Role: PI
- 2017 **Breast Fellowship Educational Research: Can the matching process between Breast Oncology Fellowship programs and candidates be simplified**
Funder: Vector Surgical
Role: Co-PI
- 2012-2019 5R01CA18800502 **Therapeutic In Situ Vaccination for Human Lymphoma**
Funder: National Institutes of Health
Role: Co-investigator

HONORS

- 1982 American College of Surgeons, Bronx Chapter
Prize, Residents' Essay Contest
- 1983 New York-Brooklyn Committee on Trauma Prize, Resident Competition Papers
- 1986 Diplomat, American Board of Surgery
- 1991 Fellow, American College of Surgeons
- 2012 Harry Dozor Visiting Scholar
Ben Gurion University of the Negev, Beer-sheva, Israel
- 2013 The Maastricht Breast Cancer Endpoint Consensus Group
- 2015 DCIS Margins Consensus Panel
- 2018-present National Cancer Institute BOLD Task Force

SOCIETIES-NATIONAL

- 1985 American College of Surgeons
- 1985 Surgical Society of the New York Medical College

1987	American Society of Breast Disease
1988-2000	American Medical Association
1989	Association for Academic Surgery
1989	Southeastern Surgical Congress
1992-2001	Medical Associate, La Leche League
1995	Society of Surgical Oncology
1992	Association of Women Surgeons
1995	Physicians for Human Rights
1999	American Society of Clinical Oncology
2002	American Association of Cancer Research
2003	American Society of Breast Surgeons
2005	Pacific Coast Surgical Association

COMMITTEES-NATIONAL

1996-2014	Breast Disease Committee NSABP-National Surgical Adjuvant Breast and Bowel Project NCI-sponsored Cooperative Oncology Group
1998-2014	Working Group Breast Committee NSABP-National Surgical Adjuvant Breast and Bowel Project /NRG NCI-sponsored Cooperative Oncology Group
2003-2015	Awards/Grant Committee Association of Women's Surgeons
2005-present	Steering Committee for IBCSG 27-02 /NSABP B-37 Clinical Trial
2005-present	Breast Fellowship Training Program Directors Subcommittee—Society of Surgical Oncology
2009-2015	Publication Committee American Society of Breast Surgeons
2011-2013	James Ewing Foundation—Corporate Relations Committee
2014-present	NRG Oncology-Surgical Oncology Subcommittee
2015-2016	NRG Oncology-Breast Committee Working Group
2015-present	NRG Oncology-Breast Committee
2015-present	NRG Oncology-Locoregional Subcommittee
2018-present	National Cancer Institute Breast Oncology Local Disease (BOLD) Task Force

COMMITTEES-EDUCATION/LOCAL

1989-2000	Cancer Committee Robert Wood Johnson University Hospital
1989-1990	Chairperson, Quality Assurance, Division of General Surgery Robert Wood Johnson University Hospital
1990	Chairperson, Clinical Research Subcommittee, The Cancer Institute—NBAH. New Brunswick Affiliated Hospitals
1992	Operating Room Committee, Robert Wood Johnson University Hospital
1993	Advisory Board, New Jersey Breast Cancer Coalition
1994	Board, Breast Cancer Resource Center
1994	Board, New Jersey Race for the Cure
1994-2000	Scientific Review Board, The Cancer Institute of New Jersey

1995	Hearing Body for Student Rights UMDNJ-Robert Wood Johnson Medical School
1999-2000	Executive Council, Oncology Society of New Jersey
2001-2002	Volunteer for Community Breast Health Project, Palo Alto, CA
2002	Women's Health @ Stanford
2003	Clinical Fellows and Residents Postdoctoral Committee
2003-present	Volunteer Clinical Faculty Appointments and Promotions Committee
2004	Stanford University School of Medicine Faculty Senate-Alternate
2004	Admissions Committee: Stanford University School of Medicine
2005	Stanford Tissue Bank Committee
2005-present	Scientific Review Committee: Stanford Cancer Center
2006	Disease Management Committee-Breast
2007-2008	Medical School Faculty Senate-Alternate
2009-2013	Senior Advisor for Women's Health @ Stanford
2010-present	Kountz Fellowship Award Committee: Department of Surgery, Stanford
2011	Survivorship Committee-Breast Disease: Stanford Cancer Center
2011-2016	Adjunct Clinical Faculty Appointments and Promotion Committee
2012-present	Breast Clinical Cancer Program (CCP): Stanford Cancer Institute
2012-present	Clinical Research Group (CRG): Stanford Cancer Institute
2013-2015	Working Group: Breast Oncology Committee
2015-present	Oncoshare Committee-Stanford Cancer Institute
2014-present	Clinical Competency Committee-General Surgery Residency Program
2016	Vice Chair of Education: Department of Surgery Search Committee, Stanford University School of Medicine
2018-present	Appointments & Promotions Committee: Department of Surgery, Stanford University School of Medicine
2018-present	Surgery Education Council: Department of Surgery, Stanford University School of Medicine
2019-present	General Surgery Residency Program Evaluation Committee: Stanford University School of Medicine
2020-present	Chair, Breast Tumor Board
2020-present	Interview Match Study Group
2020-present	Breast Oncology Search Committee: Stanford University School of Medicine
2020-present	Breast Program Steering Committee

OTHER PROFESSIONAL ACTIVITIES

1. Genomic Health, Inc. Advisory Board. September 2017. Berkeley, CA.
2. Talimogene Laherparepvec for the Treatment of Locally Recurrent Breast Cancer Advisory Board. Amgen, Inc. Advisory Board. September 2017. Madrid, Spain.
3. LHRH Development Program. Tolmar Pharmaceuticals, Inc. December 2017. San Antonio, TX.
4. The Lymphatic Mapping/Sentinel Lymph Node Biopsy Advisory Board. Cardinal Health. October 2018. Chicago, IL

EDUCATIONAL ACTIVITIES

1997	Mentor, Summer Fellowship Research Program. UMDNJ-RW Johnson Medical School
1997-2000	Chief, Ambulatory Surgery Team. UMDNJ-RW Johnson Medical School
1999-2000	Advisor, Graduate Thesis Committee. UMDNJ-RW Johnson Medical School
2000-2010	Multidisciplinary Breast Conference, Moderator-weekly. Section of Surgical Oncology
2000-present	Core Curriculum Lecture in Breast Disease
2001-present	Lecturer, core course surgical residency program
2001-present	Lecturer, medical student surgical clerkship
2002-2003	Chief, Gold Team, Division of General Surgery, Stanford University School of Medicine
2003-2014	Undergraduate and Medical Students in laboratory Alon Gavrielov–UC Berkeley Onyinye Ofor –Yale University School of Medicine Maureen Claire Chalfin–Stanford University Deshka Foster–Stanford University John Do–Stanford University
2004	Women’s Health Rotation, Department of Obstetrics and Gynecology
2004-2005	Lecturer, undergraduate, “Current topics and controversies in Women’s Health”
2005-present	Director of Breast Fellowship Stanford University School of Medicine <u>Fellows:</u> Samantha Langer, MD Laila Samiian, MD Andrea Madrigano, MD Jennifer De La Pena, MD Cassandra Erin Chow, MD Ogori Kalu, MD Caitlyn Truong, MD Anne Kieryn, MD Catherine Porter, DO Nicole Choy, MD Danielle Bertoni, MD Jacqueline Tsai, MD Abigail Hoffman, MD Rupa Patel, MD Ashley Tsang, MD Joanne Edquilang, MD Tammy Ju, MD
2006-2007	Mentor to Postdoctoral fellow Chen Yao, MD SAMFUND (Stanford University-Asia Medical Fund)
2006-2007	Mentor to Post-doctoral fellow Corinne Renier, PhD
2008-2016	Physician mentor-Stanford Immersion in Medicine Series Program
2010-2011	Mentor to Post-doctoral fellow Joanne Bueche, PhD
2010-2013	Mentor to Post-doctoral fellow Guillem Pratx, PhD
2010-present	Head of Breast Service Resident Program

2012	Lecturer Medical students: Ben Gurion University Faculty of Health Sciences
2015-2016	Mentor to Rachel Yang, MD surgical resident
2016-present	Fellows' Forum Co-Director
2019	Mentor to Yeram Park, undergraduate student
2018-2020	Mentor to Deshka Foster, MD surgical resident

Research/Grant Reviewer

2001	Susan G. Komen Breast Cancer Foundation
2003	American Cancer Society
2004-present	Association of Women Surgeons
2006	Stanford Cancer Center grant reviewer
2006	Stanford's NIH-sponsored BIRCWH (Building Interdisciplinary Careers in Women's Health)
2013-2015	Henzel-Gabor Travel Grant Committee
2019	United Kingdom Breast Cancer Now

EDITORIAL ACTIVITY

2015-present	Annals of Surgical Oncology (Editorial Board)
2019-2021	Gland Surgery (Editorial Board)
2012-2018	Case Reports in Surgery (Editorial Board)
2011	Guest Editor-Breast Diseases: A Year Book Quarterly
Ad Hoc	Annals of Surgery, Breast Cancer Research and Treatment, Endocrine-related Cancer, BMC Cancer, BMJ Cases Journal Clinical Oncology, British Journal of Cancer, Cancer, Annals in Oncology, Molecular and Cellular Endocrinology, Thyroid, Clinical Breast Cancer, Histology and Histopathology, Journal of Adolescent Health, Disease Management and Clinical Outcomes, Indian Medical Journal of Research, CA-Cancer Journal for Clinicians, Nuclear Medicine Communications, PLOS One, Journal of the American Medical Association, Journal of Surgical Oncology, BioMedical Central Surgery, the Breast Journal, Pilot and Feasibility Studies

PEER-REVIEWED PUBLICATIONS

1. Fort P, Lifshitz F, **Wapnir IL**, Wapnir RA. *Magnesium metabolism in experimental diabetes mellitus. Diabetes.* 1977 Sep;26(9):882-6. PMID: 142678
2. Ridaura-Sanz C, **Wapnir-Michalewicz IL**, Lopez-Corella E and Mendoza-Lopez E. *Muerte inesperada y sindrome de muerte subita en la infancia. Patologia (Mexico)* 1980;18:341-50. (non-Pubmed indexed, journal no longer in print)
3. Perez-Fernandez L, Pena-Rodriguez A, **Wapnir I**. *Reflujo gastro-esofagico en ninos. Experiencia en 100 casos tratados con funduplicacion de Nissen. [Gastroesophageal reflux in children. Experience in 100 cases treated by Nissen's fundoplication]. Bol Med Hosp Infant Mex.* 1985 Apr;42(4):256-65. PMID: 4005025
4. **Wapnir IL**, Pallan TM, Gaudino J, Stahl WM. *Latent mammary tuberculosis: a case report. Surgery* 1985 Nov;98(5):976-78. PMID: 4060074
5. Nallathambi MN, Ivatury RR, Lankin DH, **Wapnir IL**, Stahl WM. *Pyogenic splenic abscess in intravenous drug addiction. American Surgeon* 1987 Jun; 53(6): 342-6. PMID: 3579050

6. Ivatury RR, Nallathambi MN, Lankin DH, **Wapnir I**, Rohman M, Stahl WM. *Portal vein injuries. Non-invasive follow-up of venorrhaphy. **Annals of Surgery** 1987 Dec; 206(6): 733-7. PMID: 3318729 PMCID: PMC1493330*
7. Nallathambi MN, Ivatury RR, **Wapnir I**, Rohman M, Stahl WM. *Nonoperative management versus early operation for blunt splenic trauma in adults. **Surgery Gynecology & Obstetrics** 1988 Mar; 166(3):252-8. PMID: 3344454*
8. **Wapnir I**, Rabinowitz B, Snyderman, R. *Asymmetrical breasts in an adolescent. **Plastic and Reconstructive Surgery** 1988 May; 81(5): 813. PMID: 3363001*
9. Shah PM, **Wapnir I**, Babu S, Stahl WM, Clauss RH. *Compartment syndrome in combined arterial and venous injuries of the lower extremity. **American Journal of Surgery** 1989 Aug;158(2):136-40; discussion 104-1. PMID: 2757141*
10. **Wapnir IL**, Bancila E, Devereux DF, Greco RS. *Residual tumor and breast biopsy margins. **Breast Disease** 1989;2:81-6. (non-Pubmed indexed, journal no longer in print)*
11. **Wapnir IL**, Rabinowitz B, Greco RS. *A reappraisal of prophylactic mastectomy. **Surgery Gynecology & Obstetrics** 1990 Aug;171(2):171-84. PMID: 2200150*
12. **Wapnir IL**, Alden-Corbett S, Zicherman B, Greco RS. *Mammographic changes following biopsy and lumpectomy–breast irradiation. **New Jersey Medicine** 1993 Jan; 90(1):55-9. PMID: 8380491*
13. Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, **Wapnir I**, et al. *Collagen induced MMP-2 activation in human breast cancer. **Breast Cancer Research and Treatment** 1994;31(2-3):357-70. PMID: 7881112*
14. **Wapnir IL**, Barnard, N. *Stage II ductal carcinoma arising in a fibroadenoma. **Breast Disease** 1995;8:57-61. (non-Pubmed indexed, journal no longer in print)*
15. **Wapnir IL**. *Local recurrence after breast conservation. **Current Surgery** 1996; 53(1):8-13. (non-Pubmed indexed, journal no longer in print)*
16. **Wapnir IL**, Fang M., Zicherman B, Greco RS. *Pathologic differences in nonpalpable breast cancers detected by xeromammography and film screen mammography. **Breast Disease** 1996;9(4):203-10. (non-Pubmed indexed, journal no longer in print)*
17. **Wapnir IL**, Cody RP, Greco RS. *Superior quality of life following lumpectomy-axillary dissection in patients with stage I and stage II breast cancer. **Surgical Forum** Volume XLVII, 635-636, 1996.*
18. **Wapnir IL**, Wartenberg DE, Greco RS. *Three dimensional staging of breast cancer. **Breast Cancer Research and Treatment** 1996; 41(1):15-9. PMID: 8932872*
19. **Wapnir IL**, Southard H, Chen G, Friedman J, Boyd CD, Amenta PS. *Collagen gene expression in the neomatrix of carcinoma of the breast. **Invasion Metastasis** 1996;16(6):308-16. PMID: 9371230*
20. **Wapnir IL**, Cody RP, Greco RS. *The verbal abuse of resident physicians. **Disease Management and Clinical Outcomes** 1999;1(6):203-6. (non-Pubmed indexed, journal no longer in print)*
21. **Wapnir IL**, Cody RP, Greco RS. *Subtle differences in quality of life after breast cancer surgery. **Annals of Surgical Oncology** 1999 Jun;6(4):359-66. PMID 10379856*
22. Tazebay UH*, **Wapnir IL***, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestall RG, Carrasco N. *The mammary gland iodide transporter is expressed during lactation and in breast cancer. **Nature Medicine** 2000 Aug;6(8):871-8. PMID: 10932223 *equal first authors.*
23. **Wapnir IL**, Barnard N, Wartenberg D, Greco RS. *The Inverse Relationship between microvessel counts and tumor volume in breast cancer. **The Breast Journal** 2001 May-Jun;7(3):184-8. PMID: 11469933*
24. **Wapnir IL**, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohan O, Carrasco N. *Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas*

- using high density tissue microarrays and conventional sections. **Journal of Clinical Endocrinology and Metabolism** 2003 Apr;88(4):1880-8. PMID: 12679487
25. Cohen JB, Balzer B, **Wapnir I**, McDougall IR. *Elephantiasic pretibial myxedema*. **Thyroid** 2004 Mar;14(3):237-8. PMID: 15072707
 26. **Wapnir IL**, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, Carrasco N. *The Na⁺/I⁻ symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid*. **Clinical Cancer Research** 2004 Jul 1;10(13):4294-302. Erratum in *Clinical Cancer Research*. 2004 Nov 15;10(22):7787. Dosage error in article text. PMID: 15240514
 27. Offodile RS, Daniel BL, Jeffrey SS, **Wapnir I**, Dirbas FM, Ikeda DM. *Magnetic resonance imaging of suspicious breast masses seen on one mammographic view*. **The Breast Journal** 2004 Sep-Oct;10(5): 416-22. PMID: 15327495
 28. **Wapnir IL**, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N. *Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials*. **Journal of Clinical Oncology** 2006 May 1;24:2028-37. PMID: 16648502
 29. Ghosh M, Gambhir SS, De A, Nowels K, Goris M, **Wapnir I**. *Bioluminescent monitoring of NIS-mediated ¹³¹I ablative effects in MCF-7 xenografts*. **Molecular Imaging** 2006 Apr-Jun;5(2):76-84. PMID: 16954021 PMCID: PMC4160082
 30. Samiiian L, Daniel B, **Wapnir I**. *Resolution of hypoalbuminemia after excision of malignant phyllodes tumor*. **Clinical Breast Cancer** 2006 Dec;7(5):411-2. PMID: 17239267
 31. Altorjay A, Dohan O, Szilagyi A, Paroder M, **Wapnir IL**, Carrasco N. *Expression of the Na⁺/I⁻ symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus*. **BMC Cancer** 2007 Jan 10;7:5. PMID: 17214887 PMCID: PMC1794416
 32. Madrigano A, Westphal L, **Wapnir I**. *Egg retrieval cryopreservation does not delay breast cancer treatment*. **American Journal of Surgery** 2007 Oct;194(4):477-81. PMID: 17826059
 33. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, **Wapnir IL**, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS; Bay Area SLN Study. *New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients*. **BMC Cancer** 2008 Mar 4;8:66. doi:10.1186/1471-2407-8-66. PMID: 18315887 PMCID: PMC2311316
 34. Madrigano A, Beach B, Wheeler A, **Wapnir I**. *Metastases to the breast: Alveolar soft part sarcoma in adolescence*. **Clinical Breast Cancer** 2008 Feb;8(1):92-3. doi:10.3816/CBC.2008.n.008. PMID: 18501064
 35. **Wapnir IL**, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N; IBCSG; BIG; NSABP. *A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37*. **Clinical Breast Cancer** 2008 Jun;8(3):287-92. doi:10.3816/CBC.2008.n.035. PMID: 18650162.
 36. **Wapnir IL**, Aebi S, Gelber S, Anderson SJ, Lang I, Robidoux A, Mamounas EP, Wolmark N. *Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer*. **Annals of Surgical Oncology** 2008 Nov;15(11):3227-31. doi:10.1245/s10434-008-0129-2. [Epub 2008 Sep 11]. PMID: 18784962 PMCID: PMC2576492
 37. De La Pena J, **Wapnir I**. *Leiomyosarcoma of the breast in a patient with a 10-year history of cyclophosphamide exposure: a case report*. **Cases Journal** 2008 Nov 7;1(1):301. doi:10.1186/1757-1626-1-301. PMID: 18992149 PMCID: PMC2590612 <http://www.casesjournal.com/content/1/1/301>.

38. Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K, Gambhir SS, **Wapnir I**. *Endogenous NIS expression in triple-negative breast cancers. **Annals of Surgical Oncology** 2009 Apr;16(4):962-8. doi:10.1245/s10434-008-0280-9. [Epub 2009 Jan 28]. PMID: 19184238*
39. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, **Wapnir I**, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. *Association of reactive oxygen species levels and radioresistance in cancer stem cells. **Nature** 2009 Apr 9;458(7239):780-3. doi:10.1038/nature07733. PMID: 19194462 PMCID: PMC 2778612*
40. Anderson SJ, **Wapnir I**, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N. *Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. **Journal of Clinical Oncology** 2009 May 20;27(15):2466-73. doi:10.1200/JCO.2008.19.8424 [Epub 2009 Apr 6]. PMID: 19349544 PMCID: PMC2684852*
41. Renier C, Vogel H, Offor O, Yao C, **Wapnir I**. *Breast cancer brain metastasis express the sodium iodide symporter. **Journal of Neurooncology** 2010 Feb;96(3):331-6. doi:10.1007/s11060-009-9971-8. [Epub 2009 Jul 19]. PMID: 19618116*
42. Baynosa J, Westphal LM, Madrigano A, **Wapnir I**. *Timing of breast cancer treatments with oocyte retrieval and cryopreservation. **Journal of the American College Surgeons** 2009 Nov;209(5):603-7. doi:10.1016/j.jamcollsurg.2009.08.006. PMID: 19854400*
43. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, **Wapnir I**, Tibshirani RJ, Levy R. *In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. **Journal of Clinical Oncology** 2010 Oct 1;28(28):4324-32. doi:10.1200/JCO.2010.28.9793. [Epub 2010 Aug 9]. PMID: 20697067 PMCID: PMC2954133*
44. Beyer S, Lakshmanan A, Liu YY, Zhang X, **Wapnir I**, Smolenski A, Jhiang S. *KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells. **Endocrinology** 2011 Mar;152(3):782-92. doi:10.1210/en.2010-0782. [Epub 2011 Jan 5]. PMID: 21209020 PMCID: PMC3040054*
45. Wapnir RA, **Wapnir I**, Lifshitz F. *Eusorbents and Eusorption: A review of physiological events to therapeutic concepts. **Journal of the American College of Nutrition** 2011 Feb;30(1);1-10. PMID: 21697533*
46. **Wapnir IL**, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N. *Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. **Journal of the National Cancer Institute** 2011 Mar 16;103(6):478-88. doi:10.1093/jnci/djr027. [Epub 2011 Mar 11]. PMID: 21398619 PMCID: PMC3107729*
47. Westphal LM, **Wapnir IL**. *Integration and safety of fertility preservation in a breast cancer program. **Gynecologic Oncology** 2012 Mar;124(3):474-6. doi:10.1016/j.ygyno.2011.11.028. [Epub 2011 Nov 22]. PMID: 22173210*
48. Kalu ON, Chow C, Wheeler A, Kong C, **Wapnir I**. *The diagnostic value of nipple discharge cytology: breast imaging complements predictive value of nipple discharge cytology. **Journal Surgical Oncology** 2012 Sep 15;106(4):381-5. doi:10.1002/jso.23091. [Epub 2012 Mar 6]. PMID: 22396104*
49. Kim MJ, **Wapnir I**, Ikeda DM, Chisholm KM, Do Y, Daniel BL. *MRI enhancement correlates with high grade desmoid tumor of the breast. **The Breast Journal** 2012 Jul-Aug;18(4):374-6. doi:10.1111/j.1524-4741.2012.01255.x. [Epub 2012 Jun 20]. PMID: 22716922*
50. Cloyd JM, Hernandez-Boussard T, **Wapnir IL**. *Outcomes of Partial Mastectomy in Male Breast Cancer Patients: Analysis of SEER 1983-2009. **Annals of Surgical Oncology**. 2013 May;20(5):1545-50. doi:10.1245/s10434-013-2918-5. [Epub 2013 Mar 5]. PMID: 23460016*

51. Cloyd JM, Hernandez-Boussard T, **Wapnir IL**. *Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. **Breast Cancer Research and Treatment** 2013 May;139(1):177-82. doi:10.1007/s10549-013-2517-y. [Epub 2013 Apr 10]. PMID: 23572298*
52. Bagshaw HP, Cloyd JM, Poppe MM, **Wapnir IL**. *Radiation Therapy in Male Breast Cancer. **European Oncology & Haematology**. 2013;9(2)119-23. doi:10.17925/EOH.2013.09.2.119 (non-Pubmed indexed, journal no longer in print)*
53. **Wapnir I**, Dua M, Kierny A, Paro J, Morrison D, Kahn D, Meyer S, Gurtner G. *Intraoperative imaging of nipple perfusion patterns and ischemic complications in nipple-sparing mastectomies. **Annals of Surgical Oncology**. 2014 Jan;21(1):100-6. doi:10.1245/s10434-013-3214-0. [Epub 2013 Sep 18]. PMID: 24046104*
54. Aebi S, Gelber S, Anderson SJ, Lang I, Robidoux A, Martín M, Nortier JW, Patterson AH, Rimawi MF, Canada JM, Thurliman B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, **Wapnir IL**, CALOR investigators. *Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. **Lancet Oncology** 2014 Feb;15(2):156-63. doi:10.1016/S1470-2045(13)70589-8. [Epub 2014 Jan 16]. PMID: 24439313 PMCID: PMC3982874*
55. Do J, Foster D, Renier C, Vogel H, Rosenblum S, Doyle TC, Tse V, **Wapnir I**. *Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. **Breast Cancer Research and Treatment** 2014 Feb;144(1):93-101. doi:10.1007/s10549-014-2854-5. [Epub 2014 Feb 8]. PMID: 24510011 PMCID: PMC4363122*
56. Zhang H, Cohen AL, Krishnakumar S, **Wapnir IL**, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS. *Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. **Breast Cancer Research** 2014 Apr 7;16(2):R36. doi:10.1186/bcr3640. PMID: 24708766 PMCID: PMC4053092*
57. Yang RL, Esquivel M, Erdrich J, Lau J, Melcher ML, **Wapnir IL**. *PREDICT: Instituting an Educational Time Out in the Operating Room. **Journal of Graduate Medical Education** 2014 Jun;382-3. doi:10.4300/JgMe-D-14-00086.1. PMID: 24949168 PMCID: PMC4054763*
58. Cloyd JM, **Wapnir IL**, Read BM, Swetter S, Greco RS. *Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Cutaneous Melanoma. **Journal of Surgical Oncology** 2014 Dec;110(7):888-92. doi:10.1002/jso.23745. [Epub 2014 Aug 13]. PMID: 25124992*
59. Moosdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kuhn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, **Wapnir IL**, White JR, Smidt ML. *Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. **Journal of the National Cancer Institute** 2014 Nov 7;106(12). pii: dju288. doi:10.1093/jnci/dju288. Print 2014 Dec. PMID: 25381395 PMCID: PMC4357796*
60. Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, **Wapnir IL**. *Impact of histologic subtype on long-term outcomes of neuroendocrine carcinoma of the breast. **Breast Cancer Research and Treatment** 2014 Dec;148(3):637-44. doi:10.1007/s10549-014-3207-0. [Epub 2014 Nov 16]. PMID: 25399232*
61. Choy N, Lipson J, Porter C, Ozawa M, Kierny A, Pal S, Kao J, Trinh L, Wheeler A, Ikeda D, Jensen K, Allison K, **Wapnir I**. *Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. **Annals of Surgical Oncology** 2015 Feb;22(2):377-82. doi:10.1245/s10434-014-4034-6. [Epub 2014 Aug 28]. PMID: 25164040*
62. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, **Wapnir IL**, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. *Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy*

- for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. *Journal of Clinical Oncology* 2015 Jun 10; 33(17):1895-1901. doi:10.1200/JCO.2014.57.0085. [Epub 2015 Apr 6]. PMID: 25847929 PMCID: PMC4451172
63. Dua MM, Bertoni DM, Nguyen D, Meyer S, Gurtner GC, **Wapnir IL**. Using intraoperative laser angiography to safeguard nipple perfusion in nipple-sparing mastectomies. *Gland Surgery* 2015 Dec;4(6):497-505. doi:10.3978/j.issn.2227-684X.2015.04.15. PMID: 26645004 PMCID: PMC4647004
64. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, **Wapnir IL**. Addressing inherited predisposition for breast cancer in transplant recipients. *Journal of Surgical Oncology*. 2016 Feb 10. doi:10.1002/jso.24193. [Epub ahead of print.] PMID: 26861253
65. Shih HB, Affaf Shakir BS, **Wapnir IL**, Nguyen D. Concurrent Skin Reduction in Nipple Sparing Mastectomy and Immediate Tissue Expander Reconstruction for Grade Three Ptosis Breasts. *Journal of Aesthetic and Reconstructive Surgery*. 11 Mar 2016;(2):4 doi:10.4172/2472-1905.100013
66. Bertoni DM, Nguyen D, Rochlin D, Hernandez-Boussard T, Meyer S, Choy N, Gurtner GC, **Wapnir IL**. Protecting Nipple Perfusion by Devascularization and Surgical Delay in Patients at Risk for Ischemic Complications during nipple-sparing mastectomies. *Annals of Surgical Oncology*. 23(8): 2665-2672, 2016. doi:10.1245/s10434-016-5201-8. PMID: 27038458
67. Tsai J, Bertoni DM, Hernandez Boussard T, Telli M, **Wapnir IL**. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor positive and triple negative breast cancer. *Annals of Surgical Oncology* Oct 23(10): 3310-6, 2016. doi:10.1245/s10434-016-5449-z. [E-pub 2016 Aug 15] PMID: 27401442 PMCID: PMC5047939
68. Renier C, Do J, Reyna A, Foster D, De A, Vogel H, Tse V, Carrasco N, **Wapnir IL**. Regression of experimental NIS-expressing breast cancer brain metastases with radioiodide/gemcitabine dual therapy. *Oncotarget* 2016 Aug 23; 7(34):54811-54824. doi:10.18632/oncotarget.10238. PMID: 27363025
69. Gass J, DuPree B, Pruthi S, Bradford D, **Wapnir I**, Antoszewska R, Curtis A, Johnson N. Breast cancer survivorship: What, where and when? *Annals of Surgical Oncology* 2016 Oct;23(10):3162-7 doi:10.1245/s10434-016-5403-0. [Epub 2016 Jul 18] PMID: 27431417
70. Morrow M, Van Zee K, Solin L, Houssami N, Chavez-MacGregor M, Harris J, Horton J, Hwang S, Johnson P, Marinovich ML, Schnitt SJ, **Wapnir I**, Moran M. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ. *Journal of Clinical Oncology* 2016 Nov 20;34(33):4040-4046 doi:10.1200/JCO.2016.68.3573 [Epub 2016 Oct 31] PMID: 27528719 PMCID: PMC5477830
- [70B] *Annals of Surgical Oncology* 2016 Nov;23(12):3801-3810 doi:10.1245/s10434-016-5449-z [Epub 2016 15] PMID: 27527714
- [70C] *Practical Radiation Oncology* 2016 Sep-Oct;6(5):287-95 doi:10.1016/j.prr.2016.06.011 [Epub 2016 Jun 24] PMID: 27538810
71. **Wapnir I**, Gelber S, Anderson SJ, Lang I, Robidoux A, Martín M, Nortier JWR, Patterson A, Rimawi M, Baena Canada JM, Thurliman B, Murray E, Mamounas EP, Geyer CE, Price K, Coates AC, Gelber RD, Rastogi P, Wolmark N, Aebi S, on behalf of the CALOR investigators. Poor prognosis after second locoregional recurrences in the CALOR Trial. *Annals of Surgical Oncology*. 2017 Feb; 24(2): 398-406 doi:10.1245/s10434-016-5571-y [Epub 2016 Sep 23] PMID: 27663567 PMCID: PMC5215961
72. Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, **Wapnir IL**, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J. Clinical utility of the 12-gene DCIS Score assay: Impact on radiotherapy recommendations for

- patients with ductal carcinoma in situ. **Annals of Surgical Oncology** 2017 Mar; 24(3):660-668 doi:10.1245/s10434-016-5583-7. [Epub 2016 Oct 4] PMID: 27704370 PMCID: PMC5306072
73. Tipirneni KE, Warram JM, Moore LS, Prince A, de Boer E, Jani AH, **Wapnir I**, Liao JC, Bouvet M, Poultsides G, Behnke N, Hawn MT, Vahrmeijer A, Carroll WR, Zinn KR, Rosenthal EL. *Oncologic procedures amenable to fluorescence-guided surgery. **Annals of Surgery*** 2017 Jul; 226(1):36-47 doi:10.1097/SLA.0000000000002127 PMID: 28045715
74. **Wapnir IL**, Kurian AW, Lichtensztajn DY, Clark CA, Gomez SL. *Rising bilateral mastectomy rates among neoadjuvant chemotherapy recipients in California, 1998 to 2012. **Annals of Surgery*** 2017 Aug; 266(2):356-360 doi:10.1097/SLA.0000000000001972 PMID: 27611617 PMCID: PMC5629002
75. Unkart JT, Chen SL, **Wapnir IL**, González J, Harootunian A, Wallace AM. *Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase I study. **Annals of Surgical Oncology*** 2017 Oct; 24(11):3167-3173 doi:10.1245/s10434-017-5991-3 [Epub 2017 Jul 11] PMID: 28699134
76. Foster D, Choy N, Porter C, Ahmed S, **Wapnir IL**. *Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes. **Journal of Surgical Oncology*** 2018 Mar; 117:336-340. doi:10.1002/jso.24859 [Epub 2017 Dec 11] PMID: 29228459
77. **Wapnir IL**, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Canada JM, Thurlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; on behalf of the International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists Group; Breast International Group. *Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence (ILRR) of Breast Cancer: Final Analysis of the CALOR Trial. **Journal of Clinical Oncology*** 2018 Apr 10;36(11):1073-1079. doi:10.1200/JCO.2017.76.5719 [Epub 2018 Feb 14] PMID: 29443653
78. Lin C, Mooney K, Choy W, Yang S, Barry-Holsen K, Horst K, **Wapnir I**, Allison K. *Will oncotype Dx DCIS testing guide therapy? A single-institution correlation of Oncotype DX DCIS results with histopathologic findings and clinical management decisions. **Modern Pathology***. 2018 Apr;31(4):562-568. doi:10.1038/modpathol.2017.172 [Epub 2017 Dec 15.] PMID: 29243740
79. Yang RL, **Wapnir I**. *Hispanic Breast Cancer Patients Travel Further for Equitable Surgical Care at a Comprehensive Cancer Center. **Health Equity*** 2018 Jul 1; 2(1):109-116. doi:10.1089/heap.2017.0021. [eCollection 2018] PMID: 30283856
80. Melcher ML, Ashlagi I, **Wapnir I**. *Matching for Fellowship Interviews. **Journal of the American Medical Association***. 2018 Oct 23;320(16):1639-1640. doi:10.1001/jama.2018.13080.21596. PMID: 30422279
81. **Wapnir IL**, Khan A. *Current Strategies for the Management of Locoregional Breast Cancer Recurrence. **Oncology (Williston Park)*** 2019 Jan 17;33(1):19-25. PMID 30731014
82. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, **Wapnir IL**, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wulfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, on behalf of the KATHERINE Investigators. *Trastuzumab Emtansine for Residual Invasive HER2-positive Breast Cancer. **New England Journal of Medicine*** 2019 Feb 14;380(7):617-628. doi:10.1056/NEJMoa1814017. PMID: 30516102
83. Postolova A, Troxell ML, **Wapnir IL**, Genovese MC. *Methotrexate for Idiopathic Granulomatous Mastitis. **Journal of Rheumatology*** 2019 Jun 15. pii:Jrheum.181205. doi:10.3899/jrheum.181205. PMID: 31203215
84. Patel R, MacKerricher W, Tsai J, Choy N, Lipson J, Ikeda D, Pal S, DeMartini W, Allison K, **Wapnir IL**. *Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. **Annals of Surgical Oncology*** 2019 Aug;26(8):2452-2458. doi:10.1245/s10434-019-07419-3. PMID: 3108176

85. Koenig J, Kozak M, Sabolch A, Horst K, Tsai C, **Wapnir I**, Pollum E. *Use of preoperative radiation therapy in early-stage and locally advanced breast cancer.* **Cureus** 2019 Sep 24;11(9):e5748. doi:10.7759/cureus.5748. PMID: 31723509
86. Momeni A, Li A, Tsai J, Wan D, Karin M, **Wapnir I**. *The impact of device innovation on clinical outcomes in expander-based breast reconstruction.* **Plastic Reconstructive Surgery Global Open.** 2019 Dec 24;7(12):e2524 doi:10.1097/GOX.0000000000002524. PMID: 32537287
87. Chandler JM, Kim YJ, Bauer JL, **Wapnir IL**. Dilemma in management of hemorrhagic myositis in dermatomyositis. **Rheumatology International.** 2020 Feb;40(2):331-336. [Epub 2019 Dec 23] doi:10.1007/s00296-019-04501-7. PMID: 31872270
88. Rochlin D, Brazio P, **Wapnir I**, Nguyen D. *Immediate Targeted Nipple-Areolar Complex Reinnervation: Improving Outcomes in Gender-Affirming Mastectomy.* **Plastics and Reconstructive Surgery Global Open.** 2020 Mar 25;8(3):e2719 doi:10.1097/G. PMID: 32537367
89. Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, **Wapnir IL**, Brody JD, Levy R. *Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.* **Journal of Experimental Medicine** 2020 Sep 7;217(9):e20191712. doi:10.1084/jem.20191712. PMID: 32558897
90. Deptula P, Yesantharao P, **Wapnir I**, Nguyen D. *Staged Approach to Autologous Reconstruction in the Ptotic Breast: A Comparative Study.* **Annals of Plastic Surgery.** 2021 Jan 19. [Epub ahead of print.] doi:10.1097/SAP.0000000000002725 PMID: 33470622
91. Tevlin R, Griffin M, Karin M, **Wapnir I**, Momeni A. *Impact of incision on ischemic complications in microsurgical breast reconstruction.* **Plastic and Reconstructive Surgery** (accepted)
92. **Wapnir I**, Ashlagi I, Lo I, Roth A, Skancke E, Vohra A, Melcher M. *Interview Match Scenarios: A Thought Experiment.* **JGME** (submitted)
93. Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kummel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin A, Alcedo JC, Kuehn T, **Wapnir IL**, Fontana A, Hackmann J, Polikoff J, saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. *Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.* **Annals of Oncology** (submitted)
94. Tsang AT, Cai L, Edquiang J, **Wapnir I**. *Correlation of lumpectomy volume excised and selection a 3-dimensional interstitial tissue marker.* **Plastics and Reconstructive Surgery Global Open** (submitted)
95. Tsang AT, Cai L, Edquiang J, **Wapnir I**. *Volume restoration with a 3-dimensional interstitial marker in 134 lumpectomy operations.* **Annals of Breast Surgery** (submitted)
96. Pacjini M, **Wapnir I**, Di Martini W, Tsai J, Edquiang J, Ikeda D. *Influence of Imaging features and technique on US-guided tattoo ink marking of axillary lymph nodes removed at sentinel lymph node biopsy in women with breast cancer.* **Journal of Breast Imaging.** (submitted)
97. Tsang AT, Kingham K, Kurian AW, Ford J, **Wapnir I**. *Pathogenic variants in men with non-BRCA2-associated breast cancer.* (manuscript)
98. Telli M, Nagata H, **Wapnir I**, Archarya C, Zablotsky K, Fox B, Bifulco C, Jensen S, Ballesteros-Merino C, Le M, Pierce R, Browning E, Hermiz R, Svenson L, Bannavong D, Jaffe K, Sell J, Foerter K, Canton D, Twitty C, Osada T, Lyerly H, Crosby E. *Intratumoral plasmid IL-12 expands CD8+ T cells and induces CXCR3 signature in triple-negative breast tumors that sensitizes patient to anti-PD-1 therapy.* **Cancer Discovery** (submitted)

Other Peer Reviewed Publications

1. Gerry J, Kuo J, Jensen K, **Wapnir I**. *Vascular stromal lesion (VSL) novel discovery on breast magnetic resonance imaging. **International Journal of Case Reports and Images** 2013;4(8):436-9.* (non-Pubmed indexed, journal no longer in print)
2. Nguyen D, Ma I, Choi Y, Zak Y, **Wapnir I**. *Creating a biological implant with structures fat-augmented omental free flap. **Annals of Reconstructive and Aesthetic Surgery*** (submitted)
3. Ma IT, **Wapnir I**, Nguyen D. *Evolution in Breast Reconstruction Using the Omentum. **Annals of Breast Surgery*** (submitted)
4. Tsai J, **Wapnir I**. *Protecting nipple-areolar complex perfusion by devascularization and surgical delay **Annals of Breast Surgery*** (submitted)

Non-Peer Reviewed and/or Invited Publications

1. **Wapnir IL**, and Tan-Chiu E. *Significance of Ipsilateral Breast Tumor Recurrence. **MD Vista.com** May, 2001.*
2. **Wapnir I**, on Stuart K. *Longterm outcomes of ductal carcinoma in situ of the breast: A systematic review and meta-analysis. (ASTRO October 6, 2011). **Surgery News**, November 2011.*
3. **Wapnir I**, Anderson SA. *on Yi et al. Classification of Ipsilateral Breast Tumor Recurrences after Breast Conservation Therapy can Predict Prognosis and Facilitate Treatment Planning. (**Annals of Surgery** 253:572, 2011). **Breast Diseases: A Year Book Quarterly** 22(4): 425-426, 2011.*
4. **Wapnir I**, Dignam JJ. *on Wai ES, Lesperance ML, Alexander CS, et al. Predictors of Local Recurrence in a Population-Based Cohort of women with Ductal carcinoma In Situ Treated with Breast Conserving Surgery Alone. (**Annals of Surgical Oncology** 18:119-124, 2011). **Breast Diseases: A Year Book Quarterly** 22(4): 426-427, 2011.*
5. **Wapnir I**. *on Gholami S, Chen CH, Lou E, De Brot M, Fujisawa S, Chen NG, Szalay AA, Fong Y. Vaccinia Virus GLV-1h153 Is Effective in Treating and Preventing Metastatic Triple-Negative Breast Cancer. **Annals of Surgery**. 2012 Sep; 256 (3):437-45.*
6. **Wapnir I**, Aebi S. *on EP Mamounas, G Tang, Q Liu. The Importance of Systemic Therapy in Minimizing Local Recurrence after Breast-Conserving Surgery: The NSABP Experience. (**Journal of Surgical Oncology** 110:45-50, 2014). **Breast Diseases: A Year Book Quarterly** 25(4): 338, 2015.*
7. Yang R, Rabinowitz B, Frank M, Sims T, Thomas O, Barr N, Ganz P, Schapira L, **Wapnir I**. *Comprehensive breast cancer care for women: Piloting an educational forum for mental health professionals. **The Breast Center Bulletin** (National Consortium of Breast Centers). NO. 216. July 25, 2017.*
8. Melcher M, **Wapnir I**, Ashlagi I. (Invited Commentary) *May the Interview be with You: State your Preference. **Journal of Graduate Medical Education** 2019 Feb;11(1):39-40. doi:10.4300/JGME-D-19-00002.1 PMID: 30805095*
9. Melcher ML, Ashlagi I, Wapnir I. *Reducing the burden of fellowship interviews--Reply. **Journal of the American Medical Association**. 2019;321(11):1107. doi:10.1001/jama.2018.21596*

Contributing Investigator

1. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. *Tamoxifen in treatment of intraductal, breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. **The Lancet** 1999 Jun 12;353(9169):1993-2000 doi:10.1016/S0140-6736(99)05036-9 PMID: 10376613*

2. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N. *Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. Journal of Clinical Oncology* 1999 Nov;17(11):3374-88 doi:10.1200/JCO.1999.17.11.3374 PMID: 10550131
3. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. *Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine* 2014 Jul 10;371(2):107-18 doi:10.1056/NEJMoa1404037 [Epub 2014 Jun 1] PMID: 24881463 PMCID: PMC4175521
4. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group. *Adjuvant ovarian suppression in premenopausal breast cancer. New England Journal of Medicine*. 2015 Jan 29; 372(5):436-46 doi:10.1056/NEJMoa1412379. [Epub 2014 Dec 11]. PMID: 25495490 PMCID: PMC4341825
5. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. *Tailoring adjuvant endocrine therapy for premenopausal breast cancer. New England Journal of Medicine*. 2018 Jul 12;379(2):122-137. doi:10.1056/NEJMoa1803164. [Epub 2018 Jun 4]. PMID: 29863451
6. Mitchell SD, Willey SC, Beitsch P, Feldman S. *Evidence Based Outcomes of the American Society of Breast Surgeons Nipple Sparing Mastectomy Registry. Gland Surgery*. 2018;7(3)247-257. doi:10.21037/gs.2017.09.10

BOOK CHAPTERS

1. Wapnir IL and Jeffrey SS. Breast Surgery. *In: Anesthesiologist's Manual of Surgical Procedures*. Richard Jaffe R. and Stanley Samuels, editors. 3rd edition. Lippincott, Williams & Wilkins, Philadelphia, PA; 2003. pp 511-518.
2. Aebi S and Wapnir I. Management of Locoregional Recurrences. *In: Breast Cancer*, 2nd edition DP Winchester, CA Hudis, L Norton, editors: BC Decker Inc; Hamilton, Ontario, Canada 2006, pp 511-23.
3. Wapnir IL, De La Pena J, Jeffrey SS. Breast Surgery. *In: Anesthesiologist's Manual of Surgical Procedures*. Richard Jaffe and Stanley Samuels, editors. 4th edition. Lippincott, Williams & Wilkins, Philadelphia, PA; 645-653, 2009.
4. Julian T, Euhus D, Wapnir I (Section Editors). Section I: Etiology, Assessing Risk, Initial Evaluation and Management. *In: Kuerer's Breast Surgical Oncology*. H. Kuerer, editor. McGraw-Hill, United States. 2010, pp 3-152.
5. Kuerer HM, Pass HP, Simmons R, Kurtzman SH, Cataliotti L, Newman LA, Sclafani LM, Silverstein MJ, Tafra L, Audretsch WP, Jones RC, Kaufmann M, Macmillan RD, Boolbol SK, Schwartz GF, Kearney TJ, Rubio IT, Dietz JR, O'Higgins NJ, Rainsbury RM, El-Tamer MB, Gabram-Mendola SGA, Christiaens MR, Julian TB,

- Jakesz R, Khakpour N, Peintinger, F, Degnim AC, Montgomery LL, Hansen NM, **Wapnir IL**, Layeequr-Rahman R, Fenton AH, Sigurdson ER, von Smitten K, Czerniecki BJ, Ahrendt M, Holmes DR, Margenthaler JA, Giuliano AE, Morrow M. Multidisciplinary Training for Breast Surgical Oncology. In: Kuerer's Breast Surgical Oncology. H. Kuerer, editor. McGraw-Hill, United States. 2010, pp xxxi–xli.
6. **Wapnir IL**, Jeffrey SS. Breast Surgery. In: Anesthesiologist's Manual of Surgical Procedures. Richard Jaffe, Schmiesing C, Golianu B, editors. 5th edition. Wolters Kluwer, Philadelphia, PA; pp 659-666, 2014.
 7. **Wapnir IL**, Tsai JA, Aebi S. Locoregional Recurrence Post-Mastectomy. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. Bland K, Copeland EM, Klimberg VS, Gradishar WJ. Fifth edition. 2017, pp 808-13.
 8. Zhou M, Wapnir I, Kahn D. Blood Supply to the Nipple-Areola Complex and Intraoperative Imaging of Nipple Perfusion Patterns. In: Shiffman M. (eds) Nipple-Areolar Complex Reconstruction. Springer, Cham. 2017, pp 55-65. doi:10.1007/978-3-319-60925-6_5
 9. Stone KS, **Wapnir IL**. Male Breast Cancer. In: Grobmyer SR, eds. Complex General Surgical Oncology. [online]. Hamilton: Decker; December 2017. doi:10.2310/7800/16019. <https://www.deckerip.com/products/complex-general-surgical-oncology/>
 10. **Wapnir, IL**, Foster D, Momeni A. Breast Surgery. In: Anesthesiologist's Manual of Surgical Procedures. Richard Jaffe, Schmiesing C, Golianu B, editors. 6th edition. Wolters Kluwer. 2020, pp 729-742.

ABSTRACTS

1. Fort P, Lifshitz F, **Wapnir IL**, and Wapnir RA. Hypomagnesemia and magnesium depletion in experimental diabetes mellitus. *Diabetes* 25:363, 1976.
2. Fort P, Lifshitz F, **Wapnir IL**, and Wapnir RA. Magnesium metabolism in experimental diabetes mellitus. *J Nutr* 106(7): xxx, 1976.
3. Shah PM, **Wapnir IL**, Clauss RH, Babu SC, Stahl WM. Fasciotomy, in dual vascular injuries. *J Trauma* 23 (7): 662, 1983.
4. Ivatury RR, Rohman M, Lankin D, **Wapnir IL**, Nallathambi MN, Stahl WM. Portal vein injuries. *J Trauma* 25(7): 695, 1985.
5. **Wapnir IL**, Zicherman B, Alden S, Sussman A, Greco RS. Stellate architectural distortion after surgery. *Breast Disease* 4:53, 1991.
6. **Wapnir IL**, Southard H, Bold C, Amenta PS. Distribution of a (I) and a (III) procollagen mRNA in benign and malignant breast tissue: An in situ hybridization study. East Coast Connective Tissue Society. March 18-19, 1994, Baltimore, Maryland (poster and abstract).
7. **Wapnir IL**, Wartenberg D, Greco RS. Tumor volume analysis in breast cancer. The Cancer Institute of New Jersey Scientific Retreat. June 9, 1993, Princeton, New Jersey (poster and abstract).
8. **Wapnir IL**, Amenta P, Southard H, Boyd C. Breast Carcinoma: intratumoral localization of type I collagen by in situ hybridization. The Cancer Institute of New Jersey Scientific Retreat. June 9, 1993, Princeton, New Jersey (poster and abstract).
9. **Wapnir IL**, Johnson S, Simone A, Barnard N, MacManus S. Pregnancy-associated breast lesions. 9th International Congress on Breast Diseases, 39th Annual Clinical Conference of The University of Texas, M.D. Anderson Cancer Center, April 29 and 30, 1996, Houston, Texas (poster and abstract).
10. **Wapnir IL**, Laronga C. Reconservation for ipsilateral recurrences of breast carcinoma. The Cancer Institute of New Jersey Annual Retreat. May 31, 1996, Princeton, New Jersey (poster and abstract).
11. **Wapnir IL**, Dultz RP. Locoregional failure in elderly women with breast cancer. Society of Surgical Oncology 50th Annual Cancer Symposium. March 20-23, 1997, Chicago, Illinois (poster and abstract).

12. **Wapnir IL**, Greco RS, Owens A, Amenta P, Barnard N. Accuracy of sentinel node biopsy after neoadjuvant therapy for breast cancer. Oncology Society of New Jersey and The Academy of Medicine of New Jersey. March 3, 1999, West Orange, New Jersey.
13. Gantner A, **Wapnir IL**. Rates of axillary dissections and nodal metastasis in T1a and T1b breast cancers at Robert Wood Johnson University Hospital. Oncology Society of New Jersey. *Symposium on Clinical Cancer Research in New Jersey*. March 1, 2000, West Orange, New Jersey.
14. **Wapnir IL**, Anderson S, Tan Chiu E, Mamounas E, Flynn H, Hynes H, Hoehn J, Seay T, Wickerham DL, Fisher B, Wolmark N (National Surgical Adjuvant Breast and Bowel Project). Ipsilateral breast tumor recurrence (IBTR) and survival in NSABP node-positive breast cancer protocols. *Proceedings from American Society of Clinical Oncology 2000*; 19:82a.
15. **Wapnir IL**, Greco RS, Dohan O, Amenta P, Carrasco N. NIS Expression in Thyroid Cancer. *Proceedings from American Society of Clinical Oncology*, 2001, Vol. 20:2: 336b.
16. Goris M, Mari C, Zhu J, **Wapnir I**. Volumetric regions of interest (3D-ROI) in small animal SPECT studies: the definition of the appropriate metric at the limit of spatial resolution. *European Journal of Nuclear Medicine and Molecular Imaging* 2002; 29: S139 (abstract 344).
17. Mari C, Goris M, Chou J, **Wapnir I**. A step closer to radioiodine therapy for breast cancer. Enhancement of the Na⁺/I⁻ symporter (NIS) increases iodine uptake by human breast cancer cell. *European Journal of Nuclear Medicine and Molecular Imaging* 2002; 29: S299 (abstract 429).
18. **Wapnir I**, Anderson S, Mamounas E. Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23. *J Clin Oncol* 23, 2005 (suppl 16s; abstr 517).
19. **Wapnir I**, Dignam J, Julian T, Land S, Mamounas E, Anderson S, Margolese R, Fourchotte V, Costantino J, Wolmark N. Long-term outcomes after invasive breast tumor recurrence (I-IBTR) in women with DCIS in NSABP B-17 and B-24. *J Clin Oncol* 25:7s, 2007 (suppl 18S; abstr 520).
20. Renier C, De A, Hou L, Sun A, Prugpichailers T, Dunkel J, Gambhir SS, Tse V, **Wapnir I**. Development of a Breast Cancer Brain Metastases Model to Study ¹³¹I Radioablative Therapy. San Antonio Breast Cancer Symposium December 10-14, 2008. *Cancer Research* 69(2), Supplement 1. Abstract #2011. January 15, 2009.
21. Renier C, Sun A, Withofs N, De A, Gambhir SS, Tse V, **Wapnir I**. Evaluation of tumor uptake and retention in a mouse model of breast cancer brain metastases by ¹²⁴I PET imaging. *Cancer Research (Suppl)*, Washington DC, April 22, 2010.
22. Kalu O, Kurian AW, Chow C, Telli M, **Wapnir I**. High Percentage of Triple Negative Tumors Present as Palpable Masses. San Antonio Breast Cancer Symposium, December 8-12, 2011. *Cancer Research* 2010;70(24 Suppl):Abstract nr P6-03-01.
23. Truong C, Owens T, Kurian AW, **Wapnir I**. Excessive rates of nodal staging in DCIS. Society of Surgical Oncology. *Annals of Surgical Oncology* 2011: 18 (Suppl 1).
24. Telli ML, Kurian AW, Jensen K, Vinayak S, Flaherty P, Lipson J, **Wapnir I**, Daniel B, Carlson RW, Mills M, Chang P, Scackman E, Rocha C, Sherman B, Blackwood-Chirchir A, Bradley C, Ford JM. A phase II study of gemcitabine and carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative and BRCA 1 / 2 mutation-associated breast cancer. *Cancer Res* 2011; 71 (24 Suppl):395s.
25. **Wapnir I**, Florero M, Chao C. Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences. *J Clin Oncol* 30, 2012;[electronic publication only]. Abstract e11032, www.asco.org, www.jco.org.
26. Aebi S, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas T, Geyer Jr CE, Maibach R, Gelber RD, Wolmark N, **Wapnir I**. Chemotherapy prolongs survival for isolated local or

regional recurrence of breast cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). *Cancer Res* 72(24 Suppl): Abstract S3-2, p 96s, Dec 15, 2012.

27. **Wapnir I**, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas T, Geyer Jr CE, Maibach R, Gelber RD, Wolmark N, Aebi S. Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer) Trial. *Cancer Res* 72(24 Suppl): Abstract P-6-07, p 514 S. Dec 15, 2012.
28. Darnall B, Wheeler A, Taub C, Mackey I, **Wapnir I**, Schultz C, Rico T, Flood P. An internet-based perioperative pain psychology treatment program: results of a randomized controlled trial in breast oncology surgery patients. *J Pain*. 2016 Apr; 17(4S):S106. doi:10.1016/j. *J Pain* 2016.01.334. [Epub 2016 Mar 24].

PRESENTATIONS AND INVITED TALKS

NATIONAL-REGIONAL

1. Fasciotomy in dual vascular injuries. *New York-Brooklyn Committee on Trauma. Resident Competition papers*. December 10, 1982 (Third Prize).
2. Shah P, **Wapnir IL**, Kulkarni S, Babu S, Clauss R, Stahl MW. Angiography in the diagnosis and management of peripheral vascular trauma: New gold standard. *American College of Surgeons*, October 16-21, 1983, Atlanta, Georgia (Poster).
3. Management of dual vascular injuries of the lower extremity: A continuing challenge. Residents' Essay Contest. *American College of Surgeons-Bronx Chapter*, May 4, 1983 (Prize).
4. Shah P, Ivatury R, Ferreiro J, **Wapnir IL**, Nallathambi M, Gunduz Y. Continuous monitoring of compartment pressure. *American College of Surgeons*, October 20-25, 1984, San Francisco, California (Poster).
5. Non-operative management of adult blunt splenic trauma. *New York-Brooklyn Committee on Trauma. Residents' Competition Papers*. December 2, 1987.
6. **Wapnir IL**, Devereux DF, Greco RS. The effect of breast biopsy margins on the decision to perform breast conservation. *Oncology Society of New Jersey*, December 2, 1987.
7. Exogenous hormones and breast disease. Complexities: Evaluating and re-evaluating the breast. CME Course: UMDNJ-Robert Wood Johnson Medical School. May 10, 1989.
8. Smilow PC, Godyn JJ, **Wapnir IL**. Histopathology of non-palpable breast lesions identified by microcalcifications on mammography. *American Society of Clinical Pathologists and the College of American Pathologists*. October 28-November 3, 1989, Washington, D.C.
9. Alden S, **Wapnir IL**, Zicherman B, Sussman A, Greco RS. A comparison of mammographic changes after excisional biopsy and lumpectomy-radiation therapy. *American College of Surgeons*. October 15-20, 1989, Atlanta, Georgia (Poster).
10. **Wapnir IL**, Zicherman B, Alden S, Sussman A, Greco R. Stellate architectural distortion after breast surgery. *6th International Congress on Breast Diseases*. June 11-14, 1990, Boston, Massachusetts.
11. Breast cancer: risks and controversies. *UMDNJ-Robert Wood Johnson Medical School*. November 30, 1990.
12. Neoadjuvant chemotherapy in the treatment of breast cancer. *St. Francis Medical Center, Department of Surgery*. June 24, 1992, Trenton, New Jersey.
13. Mezrich RS, Barnard N, Nissenblatt M, Freeman E, MacManus S, **Wapnir IL**. Breast cancer prognosis by dynamic MRI. *Society of Magnetic Resonance Imaging*. March 27-31, 1993, San Francisco, California.

14. **Wapnir IL**, Wartenberg D, Greco RS. Tumor volume analysis in breast cancer. *The Cancer Institute of New Jersey Scientific Retreat*. June 9, 1993, Princeton, New Jersey (poster).
15. Closkey R, **Wapnir IL**, Greco RS. Mammography tumor size and nodal status in invasive breast cancer. *Oncology Society of New Jersey*. March 9, 1994, West Orange, New Jersey.
16. Diagnosis and surgical treatment of breast cancer in the 90's. *New Jersey Health Information Management Association Monthly Meeting*. January 20, 1995, Jamesburg, New Jersey.
17. Ductal carcinoma in situ. Surgical Grand Rounds. *St. Francis Medical Center*. April 12, 1995, Trenton, New Jersey.
18. The diagnosis and treatment of breast cancer in the 90's. *Society for Clinical Coding*, October 14, 1995, Philadelphia, Pennsylvania.
19. **Wapnir IL**, Greco RS. Breast cancer in a hormonal milieu: point/counter point. *The Tenth Annual Issues & Controversies in OB-GYN*. November 9-11, 1995, Lake Buena Vista, Florida.
20. Evaluation of breast lesions: Diagnosis & treatment. *The Tenth Annual Issues & Controversies in Ob-Gyn*, November 9-11, 1995, Lake Buena Vista, Florida.
21. Our Breasts, Our Lives. *Douglas Colloquium at Douglas College*. March 18, 1996, New Brunswick, New Jersey.
22. Clinical update: Acute surgical abdomen. *The New Jersey Health Information Management Association Annual Meeting*, June 21, 1996, Long Branch, New Jersey.
23. Johnson S, **Wapnir IL**. Presentation of breast lesions during pregnancy. (Platform Presentation) *American College of Obstetrics and Gynecology Annual District III Meeting*, Philadelphia, Pennsylvania, October 1, 1996.
24. Ductal carcinoma in situ with microinvasion. *Oncology Society of New Jersey Annual Statewide Tumor Board Meeting*, December 4, 1996.
25. The treatment of invasive breast cancer: Lumpectomy versus mastectomy – defining the differences. *International Business Communication Conference, Breast Cancer – Developing a Multi-Disciplinary Continuum of Care*, Boston, Massachusetts. June 27, 1997.
26. Ipsilateral breast tumor recurrence. *National Surgical Adjuvant Breast & Bowel Project Conference*, November 13-17, 1997, San Antonio, Texas.
27. Accuracy of sentinel node biopsy after neoadjuvant therapy for breast cancer. *Oncology Society of New Jersey and The Academy of Medicine of New Jersey*, March 3, 1999, West Orange, New Jersey.
28. **Wapnir IL**, Levy O, Amenta PS, Carrasco N. Overexpression of iodide transporter in breast cancer. *The New Jersey Breast Cancer Research Symposium*, October 29, 1999, Morristown, New Jersey.
29. **Wapnir IL**, Amenta PS, Greco RS, Yudd A, Tazebay U, Carrasco N. Immunohistochemical analysis of the I⁻ transporter in benign and malignant thyroid nodules. *Clinical Cancer Research in New Jersey. The Oncology Society of New Jersey*. March 1, 2000, West Orange, New Jersey.
30. **Wapnir IL**, Anderson S, Tan Chiu E, Mamounas E, Flynn H, Hynes H, Hoehn J, Seay T, Wickerham DL, Fisher B, Wolmark N (National Surgical Adjuvant Breast and Bowel Project). Ipsilateral breast tumor recurrence (IBTR) and survival in NSABP Node Positive Breast Cancer Protocols (B-15, B-16, B-22 and B-25). *American Society Clinical Oncology*, New Orleans, May 2000 (Poster Discussion).
31. The Role of Neoadjuvant Therapy in Invasive Breast Disease. *“What’s New in General Surgery”, 23rd Annual Postgraduate Course*. Olympic Valley, California, September 2001.
32. Significance of Ipsilateral Breast Tumor Recurrences. *“What’s New in General Surgery”, 23rd Annual Postgraduate Course*. Olympic Valley, California, September 2001.
33. Neoadjuvant therapy in breast cancer. *Salinas Valley Memorial Healthcare System*. Salinas, CA, 2002.

34. Update on treatment of small invasive breast cancers. *Watsonville Regional Hospital*, Watsonville, CA. January 2003.
35. *Northern California Tumor Board at Silverado*, Silverado, CA. March 2003.
36. Local recurrence after breast cancer. *NSABP Group Meeting*. Orlando, FL. June 27, 2003.
37. Current concepts in small invasive breast cancers. *Clinical Update: Innovations in Care*. Reno, NV. July 26, 2003.
38. Mari C, Goris M, Nabi D, Endemann G, Gavriellov A, Chou J, **Wapnir I**. Selective Targeting of Breast Cancer with Radioiodide in Nude Mice. *California Breast Cancer Research Program. Breast Cancer Research Symposium*. September 2003.
39. Treatment options for small invasive breast cancers. *Clinical Update: Innovations in Care*. San Ramon, CA. September 20, 2003.
40. Breast ductal lavage in high-risk patients. *San Ramon Regional Medical Center*. San Ramon, CA. October 23, 2003.
41. *Northern California Tumor Board at Silverado*, Silverado, CA. March 13, 2004.
42. The accuracy of sentinel node biopsy: 10 years later. *Watsonville Community Hospital*, July 12, 2004.
43. Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23. *American Society of Clinical Oncology, Platform Presentation*, Orlando, FL. May 16, 2005.
44. Local Control and Local Recurrence. *Kaiser Permanente and NSABP: A Grand Affair*. Oakland, CA. June 11, 2005.
45. *Update NSABP B-37. National Surgical Adjuvant Breast and Bowel Project Annual Meeting*. Baltimore, MD, September 17, 2005.
46. *Update NSABP B-37. National Surgical Adjuvant Breast and Bowel Project Annual Meeting*. Denver, CO. May 1, 2006.
47. McMahon D, **Wapnir I**, Karanas Y. Skin Sparing Mastectomy and Implant Reconstruction in Patients Previously Treated With Hodgkin's Disease. *California Society of Plastic Surgery/Rocky Mountain Association of Plastic Surgeons*. Mandalay Bay resort, HI, June 1-4, 2006.
48. Kryger G, Bertelson C, **Wapnir I**, Karanas Y. Immediate Single Stage Reconstruction with Acellular Dermal Matrix After Nipple Sparing Mastectomy. *California Society of Plastic Surgery/Rocky Mountain Association of Plastic Surgeons*. Mandalay Bay resort, HI, June 1-4, 2006.
49. Protocol changes B-37. *National Surgical Adjuvant Breast and Bowel Project Meeting*. Baltimore, MD. October 16, 2006.
50. Yao C, Renier C, Ribeiro-Silva A, **Wapnir I**. Co-expression of the Na/I symporter (NIS) with luminal cytokeratins and hormone receptors in invasive breast carcinoma in Chinese women. *American Association of Cancer Research*. Los Angeles. April 18, 2007.
51. *Invasive-IBTR after DCIS in NSABP Studies B-17 and B-24. Update on Protocol B-37. National Surgical Adjuvant Breast and Bowel Project*, Jacksonville, FL, April 30, 2007.
52. Madrigano A, Westphal L, **Wapnir I**. Egg retrieval cryopreservation does not delay breast cancer treatment (oral presentation). *American Society of Breast Surgeons*. Phoenix AZ, May 4, 2007.
53. **Wapnir I**, Dignam J, Julian T, Land S, Mamounas E, Anderson S, Margolese R, Fourchette V, Costantino J, Wolmark N. Long-term outcomes after invasive breast tumor recurrence (I-IBTR) in women with DCIS in NSABP B-17 and B-24. *American Society of Clinical Oncology*; platform presentation. Chicago, IL, June 4, 2007.
54. *Tahoe Forest Cancer Center Tumor Board*, Truckee, CA, August 30, 2007.

55. Julian TB, Land SR, Wang Y, Vicini FA, Arthur DW, **Wapnir I**, Dignam J, Mamounas EP, Wolmark N for the NSABP Investigators. Is boost therapy necessary in the treatment of DCIS? *ASCO Breast Cancer Symposium*, San Francisco, CA, September 7, 2007.
56. Kohrt H, Olshen R, Bermas H, Goodson W, Henry S, Rouse R, Bailey L, Philben V, Dirbas F, Dunn J, Johnson D, **Wapnir I**, Carlson R, Stockdale F, Hansen N, Jeffrey S. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. *San Antonio Breast Cancer Symposium*. December 13-16, 2007 (Poster).
57. **Wapnir IL** for NSABP, Zariw D for Biostatistical Center of IBCSG, Aebi S for IBCSG. Progress on BIG 1-02/IBCSG 27-2/NSABP B-37, A prospective randomized trial of evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. *Society of Surgical Oncology*, Oral Presentation. March 14, 2008. Chicago, IL.
58. De La Pena, Mardigrano A, Westphal L, **Wapnir I**. Comparative analysis of time delays to initiation of chemotherapy in women undergoing oocyte retrieval with cryopreservation. *Society of Surgical Oncology*, Poster Presentation. March 16, 2008. Chicago, IL.
59. De La Pena, Mardigrano A, **Wapnir I**. Triple negative breast cancers typically present as palpable masses. *American Society of Breast Disease*. April 11, 2008. San Diego, CA.
60. Renier C, De A, Hou L, Sun A, Prugpichailers T, Dunkel J, Gambhir SS, Tse V, **Wapnir I**. Development of a Breast Cancer Brain Metastases Model to Study ¹³¹I Radioablative Therapy. *San Antonio Breast Cancer Symposium*, December 13-16, 2008.
61. Systemic Therapy. Moderator. *American Society of Breast Surgery*, April 24, 2009. San Diego, CA.
62. Update on IBCSG 27-02/NSABP B-37. *Scientific Session NSABP Treatment Trials*. Atlanta, GA. November 20, 2009.
63. Expanding the use of Oncotype Dx to Node Positive Breast Cancer. *Maui Memorial Hospital*. Maui, HI. February 11, 2010.
64. Renier C, Sun A, Withofs N, De A, Gambhir SS, Tse V, **Wapnir I**. Evaluation of tumor uptake and retention in a mouse model of breast cancer brain metastases by ¹²⁴I PET imaging. *American Association of Cancer Research*, Washington DC, April 22, 2010.
65. Kalu O, Chow C, Wheeler A, **Wapnir I**. The diagnostic reliability of nipple discharge cytology. *American Society of Breast Surgeons*, Las Vegas NV, April 30, 2010.
66. Kalu O, Kurian AW, Chow C, Telli ML, **Wapnir I**. High Percentage of Triple Negative Tumors Present as Palpable Masses (Poster). *San Antonio Breast Cancer Symposium*, December 2010.
67. Truong C, Owens T, Kurian AW, **Wapnir I**. Excessive rates of nodal staging in DCIS. *Society of Surgical Oncology* (Poster). San Antonio, TX. March 3-5, 2011.
68. Lymphedema. *Breast Fellow's Institute Society of Surgical Oncology*. Cincinnati, OH. August 17-18, 2011.
69. Breast Cancer: Current Treatment Paradigms (Panelist). *American College of Surgeons Postgraduate Course 23*. October 25, 2011, San Francisco, CA.
70. Telli ML, Kurian AW, Jensen K, Vinayak S, Flaherty P, Lipson J, **Wapnir I**, Daniel B, Carlson RW, Mills M, Chang P, Schackman E, Rocha C, Sherman B, Blackwood-Chirchir A, Bradley C, Ford JM. A phase II study of gemcitabine and carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative and BRCA 1 /2 mutation-associated breast cancer. *San Antonio Breast Cancer Symposium*. San Antonio, TX. December 8-12, 2011.
71. Kierny, A, Dua M, Paro, J, Meyer S, Gurtner G, **Wapnir I**. Determining Adequate Nipple Areolar Complex Perfusion in Breast Cancer Related Mastectomies. *Society of Surgical Oncology*, Orlando, FL. March 21-24, 2012.

72. **Wapnir I** on Gholami et al. Vaccinia virus GLV 1h153 is effective in treating and preventing metastatic triple-negative breast cancer. *American Surgical Association*, San Francisco, CA. April 26, 2012.
73. Kiernyn A, Kelly C, **Wapnir I**. Small margin index is predictive of residual cancer on re-excision. *American Society of Breast Surgeons*. Phoenix, AZ. May 4, 2012.
74. Aebi S, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas T, Geyer Jr CE, Maibach R, Gelber RD, Wolmark N, **Wapnir I**. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). *San Antonio Breast Cancer Symposium*. (Oral Presentation), December 6, 2012.
75. **Wapnir I**, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas T, Geyer Jr CE, Maibach R, Gelber RD, Wolmark N, Aebi S. Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer) Trial. *San Antonio Breast Cancer Symposium*. (Poster Presentation), December 8, 2012.
76. NSABP B 37/IBCSG 27-02/ BIG 1-02 Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). *NRG Cooperative Group Meeting*. San Diego, CA, January 25, 2013.
77. Cloyd JM, **Wapnir IL**. Increasing use of lumpectomy in men with breast cancer: outcome analysis of SEER data 1983-2009. *Society of Surgical Oncology Annual Meeting (poster)*. National Harbor, MD. March 6-9, 2013.
78. Management of Locoregional Recurrence. *Society of Surgical Oncology Annual Meeting*. National Harbor, MD. March 6-9, 2013.
79. SPY Device. Innovations and Advances in Breast cancer Diagnosis and Treatment (invited oral presentation). *American Society of Breast Surgeons Annual Meeting*. Chicago, IL. May 3, 2013.
80. Fertility Preservation [Survivorship Issues]. *American Society of Breast Surgeons Annual Meeting*. Chicago, IL. May 5, 2013.
81. Porter CM, Morrison D, **Wapnir I**. The fate of DCIS after neoadjuvant treatment for invasive breast cancer. *American Society of Breast Surgeons Annual Meeting. (Poster)* Chicago, IL. May 3, 2013.
82. Telli M, Vinayak S, Kurian A, Lipson J, **Wapnir I**, Ford J. Final efficacy results from a phase II study of gemcitabine (G) and carboplatin plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA 1 / 2 mutation-associated breast cancer. *American Society of Clinical Oncology*. Chicago, IL June 8, 2013 ASCO 2013.
83. Is systemic therapy effective after locoregional recurrence? (invited) *12th International Congress for the Future of Breast Cancer*. Huntington Beach, CA. July 18, 2013.
84. Local and Systemic Management of Locoregional Recurrence. *15th Annual Lynn Sage Breast Cancer Symposium*. Chicago, IL. September 27, 2013.
85. Kort J, **Wapnir I**, Siger K, Westphal L. Five-year Cancer and Fertility Outcomes in Women who underwent Ovarian Stimulation for Fertility Preservation prior to Chemotherapy for Invasive Breast Cancer. *American Society for Reproductive Medicine*. Boston, MA. October 12-17, 2013.
86. Cancer Strategies for Triple Negative Breast Cancer. (invited) *Bayview Hunters Point 13th Annual Breast Cancer Awareness Conference*. San Francisco, CA. October 19, 2013.
87. Skin Perfusion in Breast Cancer Surgery. *SPIES Summit Meeting*. Las Vegas, NV. March 1, 2014.

88. Cloyd J, **Wapnir I**, Reade B, Greco RS. Indocyanine Green and Fluorescence Lymphangiography for Sentinel Lymph Node Identification in Melanoma. *Annual Meeting of Society of Surgical Oncology (Poster)*, Phoenix, AZ. March 13-15, 2014.
89. What's New in Breast cancer Surgery? (invited) *Salinas Memorial Medical Center*. Salinas, CA. March 28, 2014.
90. Choy N, Lipson J, Kiernyn A, Porter C, Pal S, Ikeda D, Trinh L, Ozawa M, Wheeler A, Allison K, Jensen K, **Wapnir I**. Initial results of black ink tattooing of biopsied lymph nodes. *Annual Meeting the American Society of Breast Surgeons (Poster)*, Las Vegas NV. May 3, 2014.
91. Ahmed S, Choy N, Meyer S, Porter C, **Wapnir I**. Descriptive findings on the utility of Indocyanine Green and Isosulfan Blue in the mapping of arm draining lymphatics and nodes. *Annual Meeting the American Society of Breast Surgeons (Poster)*, Las Vegas, NV. May 3, 2014.
92. Surgeon Directed Endocrine Therapy. (Meet the Professor). *Annual Meeting the American Society of Breast Surgeons*, Las Vegas, NV. May 2, 2014.
93. Surgical Management of Locoregional Recurrence. *Annual Meeting of the American Society of Therapeutic Radiation Oncology*, San Francisco, CA. September 17, 2014.
94. Choy N, Lipson J, Pal S, Ikeda, D Trinh, L Allison K, Jensen K, Ozawa M, Wheeler A, **Wapnir I**. Correlation of Percutaneously Biopsied Axillary Lymph Nodes Marked with Black Tattoo Ink Prior to Neoadjuvant Chemotherapy with Sentinel Lymph Nodes in Breast Cancer Patients. *San Antonio Breast Cancer Symposium*, San Antonio, TX, December 10, 2014.
95. Bertoni D, Hernandez-Boussard T, **Wapnir I**. Is Lymph Node Ratio Prognostic after Neoadjuvant Therapy for Breast Cancer? *Annual Meeting of the Society of Surgical Oncology*. Houston, TX, March 17, 2015.
96. Bertoni D, Nguyen D, Rochlin D, Gurtner G, **Wapnir I**. Nipple Perfusion is Preserved by Staged Devascularization in High Risk Nipple-sparing Mastectomies. *Annual Meeting the American Society of Breast Surgeons*. Orlando, FL, April 30, 2015.
97. SPY Device: What do I need to know about it? (invited) *New Technologies. Annual Meeting the American Society of Breast Surgeons*. Orlando, FL, April 30, 2015.
98. Bertoni D, Hernandez-Boussard T, **Wapnir I**. Is Lymph Node Ratio Prognostic after Neoadjuvant Therapy for Breast Cancer? *ASCO Breast Symposium*. San Francisco, CA, September 17, 2015.
99. NSABP Experience DCIS. (invited) *DCIS Margins Consensus Conference*. Chicago, IL, November 20-21, 2015.
100. Downey J, Lipson J, Ikeda D, **Wapnir I**. A technique for preoperative axillary lymph node tattooing in patients with breast cancer. *San Antonio Breast Cancer Symposium* December 10, 2015.
101. Manders J, Kuerer H, Smith BD, McCluskey C, Farrar W, Frazier T, Li L, Leonard CE, Carter D, Chawla S, Medeiros L, Guenther MJ, Castellini L, Buchholz D, Mamounas E, **Wapnir IL**, Horst K, Chagpar A, Evans S, Riker A, Vali F, Solin L, Jablon L, Recht A, Sharma R, Lu R, Sing A, Hwang ES, White J. The 12-gene DCIS Score Assay: Impact on Radiation Treatment (XRT) Recommendations and Clinical Utility. *San Antonio Breast Cancer Symposium*. December 12, 2015.
102. Preserving Fertility during Breast Cancer and Pregnancy after Breast Cancer (Invited) *The Evolving World of Survivorship. Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX. April 14, 2016.
103. A Positive Sentinel Node: Should NOT have ALND and Should NOT have Axillary Radiation. (Invited) *Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX. April 16, 2016.
104. Yang R, Rhoads KR, **Wapnir I**. Equitable surgical breast cancer care for Hispanic patients who travel to NCI-designated Comprehensive Cancer Center. *Annual Meeting of the American Society of Breast*

- Surgeons*. Dallas, TX. April 15, 2016.
105. Tsai J, Bertoni D, Hernandez-Boussard T, **Wapnir I**. Disease-free Survival using Lymph Node Ratio Analysis after Neoadjuvant Chemotherapy. *Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX. April 15, 2016.
 106. **Wapnir I**, Kurian A, Lichtensztajn D, Clarke C, Lin, SG. Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy (NAC) in California, 1998-2012. *Annual Meeting of the American Society of Clinical Oncology*, Chicago, IL, June 3-6, 2016.
 107. **Wapnir I**, Kingham KE, Mills ME, Ford J, Kurian AW. Molecular Receptor Profiles in Male Mutation Carriers with Breast Cancer. *Annual Meeting of the American Society of Breast Surgeons*. Las Vegas, NV, April 28, 2017.
 108. Hoffman A, Aleshin A, Banks K, Talasaz AA, Eltoukhy H, Telli M, **Wapnir I**. Circulating Tumor DNA and Burden of Disease in Breast Cancer. *Annual Meeting of the American Society of Breast Surgeons*, Las Vegas, NV, April 28, 2017.
 109. Fertility Preservation Issues. (Invited) *Annual Meeting of the American Society of Breast Surgeons*. Las Vegas, NV, April 30, 2017.
 110. **Wapnir I**, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Cañada JMB, Thurlimann BJK, Mamounas EP, Geyer CE, Gelber SI, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi SP. Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial. [Poster Discussion] *American Society of Clinical Oncology Annual Meeting*. Chicago, IL, June 4, 2017.
 111. Sue G, Winton L, **Wapnir IL**. Critical analysis of nipple-areola complex morphology. *American Society Plastic Surgery Annual Meeting*. Orlando, FL, October 6, 2017.
 112. Manders J, Kuerer H, Smith B, McCluskey C, Farrar W, Frazier T, Li L, Leonard C, Carter D, Chawla S, Medeiros L, Guenther JM, Castellini L, Buchholz D, Mamounas EP, **Wapnir I**, Horst K, Chagpar A, Evans S, Riker A, Vali F, Solin L, Jablon L, Recht A, Sharma R, Lu R, Turner M, Baehner F, Hwang ES, White J. Refined estimates of local recurrence risk in a clinical utility study: the integrated prognostic score incorporating the DCIS Score™ result, patient age, and DCIS tumor size. *San Antonio Breast Cancer Symposium*. San Antonio, TX, December 2017.
 113. Patel R, Tsai J, Choy N, Pal S, Lipson J, **Wapnir I**. The Role of Tattooing Biopsied Axillary Lymph Nodes in Patients Undergoing Neoadjuvant Therapy. *San Antonio Breast Cancer Symposium*. San Antonio, TX, 08 December 2017.
 114. Yang R, Rabinowitz B, Frank M, Sims T, Thomas O, Barr N, Ganz P, Schapira L, **Wapnir I**. Bridging Gaps in Breast Cancer Care: A Pilot Forum for Mental Health Professionals. *San Antonio Breast Cancer Symposium*. San Antonio, TX, December 2017.
 115. Breast Cancer Panel. *18th Multidisciplinary Management of Cancers: A Case-Based Approach Conference*. Napa, CA, March 16-18, 2018.
 116. Town Hall Session Moderator: Opportunities for California Multi-institution Surgical Quality Collaborations. *Northern California Chapter of the American College of Surgeons*. Berkeley, CA, April 6-7, 2018.
 117. Telli M, Zablotsky K, Gargosky S, Twitty C, **Wapnir I**. Intratumoral plasmid IL-12 and electroporation in pretreated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC). [Poster Presentation] *American Association of Cancer Research*. Chicago, IL, April 14-18, 2018.
 118. Ferrer J, Hwang S, Hunt K, Dodge D, Chapgar A, Grobmyer S, Karp S, Valente S, **Wapnir I**, Smith K, Ramirez E, Bischof T, Strasfeld D, Lee D, Smith B. Expansion into Multiple Institutions for Training in the

- use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects with Breast Cancer. *American Association of Cancer Research Annual Meeting*. Chicago, IL, April 14-18, 2018.
119. Telli M, Zablotsky K, Gargosky S, Twitty C, **Wapnir I**. Intratumoral Plasmid IL-12 and Electroportation in Pre-treated Inoperable Locally Advanced or Recurrent Triple-Negative Breast Cancer (TNBC). *American Association of Cancer Research Annual Meeting*. Chicago, IL, April 14-18, 2018.
120. Session Moderator: Management of Recurrent Breast Cancer. *American Society of Breast Surgeons 19th Annual Meeting*. Orlando, FL, May 6, 2018.
121. Patel R, Tsai J, Choy N, Pal S, Lipson J, **Wapnir I**. The Role of Tattooing Biopsied Axillary Lymph Nodes in Patients Undergoing Neoadjuvant Therapy. *American Society of Breast Surgeons 19th Annual Meeting*. Orlando, FL, May 6, 2018.
122. Telli M, Zablotsky K, Fox B. Le M, Browning E, Bannawong D, Canton D, Foerter K, Svenson L, **Wapnir I**. Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer. *San Antonio Breast Cancer Symposium*. San Antonio, TX, December 4-8, 2018.
123. Telli M, **Wapnir I**, Vinayak S, Solima H, Cuff K, Devitt B, Twitty C, Malloy Foerter K, Joshi R. A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple-negative breast cancer. *San Antonio Breast Cancer Symposium*. San Antonio, TX, December 4-8, 2018.
124. Esquivel M, Yang R, Erdrich J, Lau J. Melcher M, **Wapnir I**. Perioperative Educational Time Out: Building an Educational Framework. [Podium Presentation] *Academic Surgical Congress*. Houston, TX, February 2019.
125. Smith K, Ferrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, **Wapnir I**, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski B, Chagpar An, Karp S, Schlossberg B, Gjylameti L, Smith B. Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. *AACR Annual Meeting 2019*. Atlanta, GA, March 29-April 3, 2019.
126. Melcher M, Lo I, **Wapnir I**, Skancke E, Roth A, Ashlagi I. Safely Reducing the Interview Burden in the Match. *2019 Surgical Education Week, Association of Program Directors in Surgery*. Chicago, IL, April 23-27, 2019.
127. **Wapnir I**, Lo I, Roth A, Ashlagi I, Melcher M. Benefits of an Interview Match for Breast Fellowship Positions. *20th Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX, April 30-May 5, 2019.
128. Tsang, A, Kingham K, Kurian A, Ford J, **Wapnir I**. Clinical and Pathological Features of Breast Cancer Among Men and Women with ATM and CDH1 Mutations. *20th Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX, April 30-May 5, 2019.
129. Smith, B, Kelly B, Hunt K, Hwang S, **Wapnir I**, Gadd M, Specht M, Hughes K, Lanahan C, Brown C, et al. Preliminary Results of Multi-Center Feasibility Trial for Real-Time, Intraoperative Detection of Residual Breast Cancer in Lumpectomy Cavity Margins using the LUM Imaging System. *20th Annual Meeting of the American Society of Breast Surgeons*. Dallas, TX, April 30-May 5, 2019.
130. Foster D, **Wapnir I**. Endogenous Breast Cancer Shows Clonal Proliferation of Cancer Associated Fibroblasts at Primary Tumor and Metastatic Sites. *October 28, 2019 Scientific Forum*
131. Telli M, **Wapnir I**, Algazi A, Sell J, Baker C, Bannavong D, Twitty C. Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous

- pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC). *2019 San Antonio Breast Cancer Symposium*. San Antonio, TX. December 10-14, 2019.
132. Smith K, Ferrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, **Wapnir I**, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski B, Chagpar An, Karp S, Schlossberg B, Gjylameti L, Smith B. Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. *2019 San Antonio Breast Cancer Symposium*. San Antonio, TX. December 10-14, 2019.
133. Untch M, Conlin A, Liu H, von Minckwitz G, Yang Y, Smitt M, Kuemmel S, Saghatchian-Dassignies M, Strunk C, Blotner S, Geyer C, Wolmark N, Huang C, Tesarowski D, Lam L, **Wapnir I**, DiGiovanna M, Mamounas E, Zimovjanova M, Loibl S, Mano M, Song C. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. KATHERINE subgroup analysis. *2019 San Antonio Breast Cancer Symposium*. San Antonio, TX. December 10-14, 2019.
134. **Wapnir I**, De Martini W, Allison K, Stone K, Dirbas F, Marquez C, Ikeda D, Pal S, Tsai J, Yang R, West R, McMillan A, Telli M, Horst K. A randomized phase II study comparing surgical excision versus **NeO**adjuvant Radiotherapy followed by delayed surgical excision of **D**uctal carcinoma **I**n **S**itu (**NORDIS**). *San Antonio Breast Cancer Symposium*. San Antonio, TX. December 10-14, 2019.
135. New techniques for improving margin assessment in breast conserving surgery. *19th Annual International Congress on the Future of Breast Cancer West*. Aug 1, 2020 (Lecture: video format)

INTERNATIONAL

1. **Wapnir IL**, and Carrilo J: Poliposis juvenil multiple. *XIII Congreso Nacional de Patologia*, Guadalajara, Jal., Mexico, May 1980 (Poster).
2. Perez LF, Pena A, and **Wapnir IL**. Perspectivas del tratamiento de la enfermedad por reflujo gastroesofagico en el nino. *XI Congreso Mexicano de Cirugia Pediatrica*, Taxco, Gro., Mexico, September 1980.
3. Dohan O, Paroder M, Altorjay A, Fineberg S, **Wapnir IL**, Carrasco N. Sodium iodide transporter (NIS) expression in thyroid, gastroesophageal and breast tumors. *Merc-European Thyroid Meeting*. Budapest, Hungary, June 2000.
4. De la Vieja A, Dohan O, Ginter C, Riedel C, Tazebay U, **Wapnir IL**, Carrasco N. Molecular analysis and pathophysiological relevance of the sodium/iodide symporter (NIS). *International Thyroid Meeting*. Kyoto, Japan, October 2000.
5. Goris M, Mari C, Zhu J, **Wapnir I**. Volumetric regions of interest (3D-ROI) in small animal SPECT studies: the definition of the appropriate metric at the limit of spatial resolution. *European Association of Nuclear Medicine*. September 2002.
6. Mari C, Goris M, Chou J, **Wapnir I**. A step closer to radioiodine therapy for breast cancer. Enhancement of the Na⁺/I⁻ symporter (NIS) increases iodine uptake by human breast cancer cells. *European Association of Nuclear Medicine*. September 2002.
7. Dohan O, **Wapnir I**, Carrasco N. Na⁺/I⁻ symporter (NIS)-mediated therapy in non-thyroid cancers: endogenous and gene transfer approaches. *International Endocrine Society*. September 2004.
8. Diagnosis and Surgical Treatment of Breast Cancer. *The Philippines Senate*. Manila, Philippines. March 3, 2008.
9. Diagnosis and Surgical Treatment of Breast Cancer. *Polo Club*. Manila, Philippines. March 3, 2008.
10. Diagnosis and Surgical Treatment of Breast Cancer. *Makati Hospital*. Manila, Philippines. March 4, 2008.

11. Diagnosis and Surgical Treatment of Breast Cancer. *Chinese Hospital*. Manila, Philippines. March 5, 2008.
12. *Advances in Breast Cancer–Manila Forum*; Manila, Philippines. March 5, 2008.
13. NSABP Breast Cancer Clinical Trials: Past and Present. Department of Oncology. *Soroka Medical Center, Ben Gurion University of the Negev*. Beer Sheva, Israel. December 17, 2012.
14. Advances in Breast Cancer Surgery. Grand Rounds. *Soroka Medical Center, Ben Gurion University of the Negev*. Beer Sheva, Israel. December 19, 2012.
15. Advances and Controversies in Breast Cancer Care. *Assuta Medical Center*. Tel Aviv, Israel. December 19, 2012.
16. Surgical Management of Breast Disease. Lecture for Department B Surgery. *Barzilai Medical Center*. Ashkelon, Israel. December 23, 2012.
17. Surgical Management of Breast Disease. Lecture for Department B Surgery. *Soroka Medical Center, Ben Gurion University of the Negev*. Beer Sheva, Israel. December 25, 2012.
18. Controversies in Surgery after Neoadjuvant Therapy. Department of Breast Oncology. *Hadassah Hospital*. Jerusalem, Israel. August 29, 2019.

STANFORD

1. NIS and its Therapeutic Implications. *Nuclear Medicine Grand Rounds. Department of Radiology, Stanford University school of Medicine*. March 30, 2004.
2. Breast augmentation: an epidemic? *Women's Health Studies, Stanford University*. April 29, 2004.
3. Breast Disease and Older Women. Improving the Health of Older Women of Color. *Stanford University*. December 11, 2004.
4. Work-Up of Abnormal Findings. *Clinical Breast Examination: Proficiency and Risk Management*. Stanford, CA. April 9, 2005.
5. Current Topics and Controversies in Women's Health. *Stanford University*. April 27, 2005.
6. Advancing the cure through breast cancer research. *Stanford Cancer Center*. October 28, 2005.
7. Changing Paradigms in Breast Cancer Therapy. *Department of Surgery Grand Rounds. Stanford University School of Medicine*. April 4, 2006.
8. Treatment of Benign and Malignant Breast Disease. *Obstetrics and Gynecology, Stanford University*. May 8, 2006.
9. Advances in Breast Cancer Treatment Strategies. *Women's Health Program. Stanford University*. August 17, 2006.
10. Stage-specific Treatment of Breast Cancer. *Stanford Cancer Education Series. Stanford University*. October 10, 2007.
11. Renier C, De, A, Dunkel J, Hou L, Prugpichailers T, Sun A, Gambhir SS, Tse V, **Wapnir I**. Developing and imaging brain metastasis in a mouse model with iodide-transporting/ER-negative breast cancer cell lines. *Stanford Cancer Center Annual Retreat*. April 7, 2008.
12. Timek E, **Wapnir I**, Gurtner G. SPY-ring adequate tissue perfusion with intraoperative fluorescent laser angiography in immediate breast reconstruction. *Stanford Cancer Center Annual Retreat*. April 7, 2008.
13. NIS Therapeutics in Breast Cancer. *Nuclear Medicine Grand Rounds*. March 9, 2009.
14. Ductal carcinoma in situ. *Grand Rounds Department of Surgery*. January 26, 2010.
15. Malignant Breast Disease: A Perspective for the Gynecologist. *Grand Rounds Obstetrics and Gynecology*. April 2010.
16. Women's Health Forum. Moderator. *Stanford University*. May 5, 2010.

17. Evolving Standards for In Situ Cancer. *Surgical Quality, Best Practice and Innovation*. Stanford, CA. September 10, 2010.
18. Surgical Treatment of Breast Cancer. *Advanced Lymphedema Management Course*. Stanford University School of Medicine. September 23, 2010.
19. The Role of Surgery in the Treatment of Breast Cancer. *Cancer Education Series*. October 2010.
20. Triple Negative Breast Cancer. *Grand Rounds Department of Surgery*. March 6, 2011.
21. What to do about Stage 0 Breast Cancer? *Women's Health Forum*. Arrillaga Alumni Center, Stanford University. May 11, 2011.
22. Surgical Treatment of Breast Cancer. *Advanced Lymphedema Management Course*. Stanford University School of Medicine. October 18, 2011.
23. Kieryn A, Dua M, Paro J, Meyer S, Gurtner G, **Wapnir I**. Determining Adequate Nipple Areolar Complex Perfusion in Skin Sparing Mastectomies. *CBIS*. April 5, 2012.
24. The Risks and Benefits of Prophylactic Mastectomy. *Women's Health Forum*. Stanford University School of Medicine. May 9, 2012.
25. Surgical Treatment of Breast Cancer. *Advanced Lymphedema Management Course*. Stanford University School of Medicine. October 5, 2012.
26. Early Breast Cancer Therapy. *Cancer Education Series*. Stanford University School of Medicine. October 30, 2012.
27. Surgical Management of Breast Cancer. *Department of Radiation Oncology*. Stanford University School of Medicine. January 18, 2013.
28. The changing Role of Surgery in Breast Cancer. *Women's Health Forum*. Stanford University. Stanford, CA. May 15, 2013.
29. Surgical Treatment of Breast Cancer. *Advanced Lymphedema Management Course*. Stanford University School of Medicine. October 25, 2013.
30. Mastectomies on the Rise. *Department of Surgery Grand Rounds*. January 27, 2015.
31. Que es Cancer? Tratamientos a traves de ensayos clinicos. *Stanford Cancer Institute*. April 24, 2015.
32. Webinar with the Philippines Breast Society on Genetics of Breast Cancer. October 26, 2015.
33. Principles Of Local Therapy In Early Breast Cancer. *Cancer Education*. October 27, 2015.
34. Surgical Treatment of Breast Cancer. *Conference in Lymphology, Research in Physical Treatment of Lymphedema, Breast Cancer Surgery, Therapy for Breast Cancer*. November 6, 2015.
35. Stanford Cancer Institute. *Estudios o Ensayos Clinicos: Cancer de Mama*. April 21, 2016.
36. *Two stage Nipple-sparing Mastectomy*. Fellows' Forum. LKSC, Stanford School of Medicine. May 25, 2016.
37. *Skin Perfusion Imaging in Mastectomy Surgery*. American Society of Image Guided Surgery 2016: Surgical Navigation Update. Stanford Medicine. July 26, 2016.
38. *What do breast surgeons need from breast imagers?* Radiology Resident Didactic Lecture Series. Department of Radiology. Stanford School of Medicine. March 8, 2018.
39. *Omentum-based Breast Reconstruction* (co-presenter Dung Nguyen MD). Department of Surgery Grand Rounds. September 22, 2020.
40. *Breast Cancer Detection and Treatment*. Department of Obstetrics and Gynecology Grand Rounds. Santa Clara Valley Medical Center, Santa Clara, CA. November 12, 2020.

COMMUNITY OUTREACH

1. Breast cancer awareness: A challenge for life. *American Cancer Society*. July 27, 1991, Rahway, New Jersey.
2. Cancer: Researching the Cure. *Annual Meeting Order of Eastern Star*. Fresno, CA. October 20, 2005.
3. Women, Jewish Ancestry and Breast Cancer. *Jewish Federation of Silicon Valley*. Los Gatos, CA. October 27, 2005.
4. Breast Cancer 2009. *Women's Business Conference*, October 21, 2009. Sonora, CA.
5. Factors Affecting Latino Participation in Clinical Trials-The Clinical Perspective: Breast cancer. *Latinas Contra Cancer*. Santa Clara Valley Medical Center, Santa Clara, CA. March 12, 2010.
6. Contributions of Surgery to Breast Cancer Survivorship. Stanford Health Library, *Oshman Family Jewish Community Center*, Palo Alto CA. January 13, 2011.
7. Triple Negative Breast Cancer and Young Women. *7th Annual African American Breast Cancer Conference*. Oakland, CA. May 7, 2011.
8. Survivorship after Breast Cancer. *Tuolumne County's Women's Network*. Sonora, California. October 17, 2012.
9. What is Jewish about Breast Cancer? *Israel Cultural Center at Oshman Family Jewish Community Center*. Palo Alto, CA. December 17, 2013.
10. Breast Cancer Awareness: What's Jewish about Breast Cancer? *The Reutlinger Community Center*. Danville, CA. October 26, 2017.

IN THE NEWS

1. Breast cancer patients needed for trial to assess imaging technique for mastectomies. *Stanford Medicine*, August 2009.
2. News from the American College of Surgeons: November 12, 2009. *Fertility Procedures Need Not Delay Breast Cancer Treatment for Younger Women*
3. Breast Cancer Network News. *DCIS Patients Who Get Invasive Breast Cancer Have Higher Mortality*. BCNN.com, March 14, 2011.
4. Best Breast Cancer Journal Articles of the Year. Research to Practice: Year in Review Breast Cancer. *Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS*. *Journal of the National Cancer Institute* 103(6): 478-488, March 16, 2011. <http://www.researchtopractice.com/>.
5. McNeil C. *DCIS Patients Who Get Invasive Breast Cancer Have Higher Mortality*. *JNCI* 103 (6), 2011.
6. In this Issue. *Treatment of DCIS*. *JNCI* 103 (6): 449, 2011.
7. Fast Facts for Health Professionals. *On ductal carcinoma in situ (DCIS)*. DC Cancer Consortium. Department of Health District of Columbia. September 30, 2011.
8. Front Page: *Triple Negative Breast Cancer*. Los Angeles radio station KJLH. September 30, 2011.
9. Lasting impressions: *Wapnir on the memory of a breast cancer patient*. *Stanford Medicine*, October 2011.
10. Research to Practice with Dr Neil Love. Breast cancer management. August 28, 2014 (Audio Recording).
11. Wall Street Journal. Overtreatment of Breast Cancer. September 11, 2014.
12. Top Doctors. *San Francisco Magazine*. December 2014.
13. MundoFox. Interview about Cancer Clinical Trials. March 2015.
14. Telemundo. Interview about Cancer Clinical trials. April 21, 2015.
15. Newsweek Health: Top Cancer Doctors 2015. *Newsweek Cancer 2015 Issue*. July 31, 2015.
16. *Survivornet.com*. Interview at San Antonio Breast Cancer Symposium 2017.

17. Touchmedicalmedia.com. Interview about locoregional recurrence of breast cancer at San Antonio Breast Cancer Symposium 2017.
18. CongressReport.eu. Interview at San Antonio Breast Cancer Symposium 2017.
http://filmek.olo.hu/SABCS_2017/SABCS_Irene_Wapnir_int_x264.mp4
19. Top Doctors. *San Francisco Magazine*. January 2018.
20. Generalsurgerynews.com. Interview 'Modern Era' Data Should Inform Decisions on Breast-Conserving Surgery. <https://www.generalsurgerynews.com/Web-Only/Article/07-18/-Modern-Era-Data-Should-Inform-Decisions-on-Breast-Conserving-Surgery/51276?sub=18E7FB1A527168544982D7F41C1119F814087B7DEC8C48F7461CD6DDBC3B283&enl=true>
21. Survivornet.com. <https://www.survivornet.com/author/dr-irene-wapnir/>
22. Stanford Medicine Scopeblog. <https://scopeblog.stanford.edu/2018/09/21/the-current-fellowship-interview-process-is-cumbersome-stanford-researchers-have-a-better-idea/>
23. Clinicaloncology.com. Finding the Drivers of Locoregional Recurrence of Breast Cancer, Importance of Tumor Burden Overestimated. <https://www.clinicaloncology.com/Breast-Cancer/Article/11-18/Finding-the-Drivers-of-Locoregional-Recurrence-Of-Breast-Cancer/53316?sub=--esid--&enl=true>
24. GeneralSurgeryNews.com. Algorithm Could Streamline Fellowship Interview Process. <https://www.generalsurgerynews.com/In-the-News/Article/06-19/Algorithm-Could-Streamline-Fellowship-Interview-Process-/55180>
25. Stanford Medicine Scopeblog. <https://scopeblog.stanford.edu/2019/12/02/stanford-surgeons-innovate-new-biological-breast-implants/>